Heterocyclic modulators of lipid synthesis

Abstract

20 26 22 33 82 31 A ug 2 02 6 H E T E R O C Y C L I C M O D U L A T O R S O F L I P I D S Y N T H E S I S A B S T R A C T 2 0 2 6 2 2 3 3 8 2 3 1 2 0 2 6 A u g

Description

2026223382   31 Aug 2026 RELATED APPLICATIONS

[0001] The present application is a divisional of Australian Patent Application No 2024201067, which is a divisional of Australian Patent Application No 2017356214, which is the national phase application of International Patent Application No PCT / US2017 / 061330, which claims priority to, and the benefit of, US Provisional Application No 62 / 574,497, filed 19 October 2017; and US Application No 15 / 349,960, filed on 11 November 2016, which is continuation in part of US Application No 14 / 874,961, filed on 5 October 2015, which is a continuation of US Application No 14 / 315,133, filed on 25 June 2014, now abandoned, which is a continuation of US Application No 13 / 415,660, filed 8 March 2012, now US Patent No 8,871,790, which claims the benefit of the earlier filed US Provisional Application No 61 / 450,561 filed on 8 March 2011, US Provisional Application No 61 / 508,611, filed on 16 July 2011, and US Provisional Application 61 / 585,642, filed on 11 January 2012; is a continuation in part of US Application No 15 / 201,824, filed on 5 July 2016, which is a divisional of US Application No 14 / 587,908, filed on 31 December 2014, now US Patent No 9,428,502, which is a continuation of PCT / US2013 / 048950, filed on 1 July 2013, which claims the benefit of the earlier filed US Provisional Application No 61 / 667,894, filed on 3 July 2012, US Provisional Application No 61 / 698,511, filed on 7 September 2012, US Provisional Application 61 / 699,819, filed on 11 September 2012, and US Provisional Application 61 / 785,933, filed on 14 March 2013; and is a continuation in part of US Application No 15 / 110,154, filed on 7 July 2016, which is a US National Phase application, filed under 35 U.S.C. § 371, of PCT / US2015 / 010459, filed on 7 January 2015, which claims the benefit of the earlier filed US Provisional Application No 61 / 924,520, filed on 7 January 2014.

[0002] The entire contents of each of these applications are incorporated by reference in their entireties for all purposes. FIELD

[0003] The present disclosure relates generally to heterocyclic modulators of lipid synthesis and methods of use thereof. The present heterocyclic modulators of lipid synthesis can be used for the treatment of disorders characterized by dysregulation in the fatty acid synthase function in a subject by modulating the fatty acid synthase pathway and / or the fatty acid synthase function. BACKGROUND

[0004] Viral disease is a significant health concern that threatens large segments of human populations. Some of the features related to viral infection which are of concern to health care professionals include its highly contagious nature (e.g., HIV, SARS, etc.) and high mutability. 2026223382   31 Aug 2026 Some viruses are also oncogenic (such as HPV, EBV and HBV). While viruses are structurally amongst the simplest of organisms, they are regarded to be among the most difficult to control and present a formidable challenge for antiviral drug R&D.

[0005] Thus far, there have been a few antiviral drugs widely used in patients, such as Amantadine and Oseltamivir for influenza, Acyclovir for HSV-related infections, Ganciclovir for CMV infection, and multiple agents including co-formulated drugs (Efavirenz, emtricitabine, and tonfovir disoproxil fumarate) for AIDS treatments. These drugs possess a variety of undesirable neurological, metabolic and immunological side-effects. Therefore, development of new antiviral therapy has become a major focus of medical and pharmaceutical research and development.

[0006] Infection by hepatitis C virus (HCV) is a serious health issue. It is estimated that 170 million people worldwide are chronically infected with HCV. HCV infection can lead to chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. Chronic HCV infection is thus a major worldwide cause of liver-related premature mortality.

[0007] The present standard of care treatment regimen for HCV infection involves combination therapy with interferon-alpha and ribavirin, often with the addition of a direct-acting protease inhibitor (Telaprevir or Boceprevir). The treatment is cumbersome and sometimes has debilitating and severe side effects. For this reason, many patients are not treated in early stages of the disease. Additionally, some patient populations do not durably respond to treatment. New and effective methods of treating HCV infection are urgently needed.

[0008] The dominant therapeutic approaches that are currently employed to treat cancer include surgical removal of primary tumors, tumor irradiation, and parenteral application of anti-mitotic cytotoxic agents. Unfortunately, only a relatively small cross-section of cancer patients have tumors that are “addicted” to a specific pathway, and can therefore be treated with newer targeted agents. The continued dominance of these long established therapies is mirrored by the lack of improvement in survival rates for most cancers. In addition to limited clinical success, devastating side effects accompany classic therapies. Both radiation- and cytotoxic-based therapies result in the destruction of rapidly dividing hematopoietic and intestinal epithelial cells leading to compromised immune function, anemia, and impaired nutrient absorption. Surgical intervention often results in a release of tumor cells into the circulation or lymph systems from which metastatic tumors can subsequently be established. Improved methods for the treatment of cancer are needed. 2026223382   31 Aug 2026

[0009] Non-alcoholic liver disease (NAFLD), a condition in which the liver contains more than 5% fat by weight and is not caused by alcohol consumption, is a disease which currently affects -20-30% of the US and general western world population, and is associated with a significant increased risk of morbidity extending beyond the liver to cardiovascular disease (i.e., carotid atherosclerotic plaques and endothelial dysfunction), chronic kidney disease and malignancy. Obesity and metabolic syndrome are two key risk factors for NAFLD which are characterized as an imbalance in energy utilization and storage. This imbalance leads to dysregulated metabolic pathways and inflammatory responses that drive further changes leading to liver damage and comorbid conditions. Along with the progression of metabolic syndrome, NAFLD leads to more advanced liver disease starting with non-alcoholic steatohepatitis (NASH) which can then progress to significant liver diseases including cirrhosis and hepatocellular carcinoma.

[0010] The synthesis of fatty acids in the liver, a pathway termed hepatic de novo lipogenesis (DNL), is increased in subjects with metabolic syndrome and NAFLD (Donnelly, K. L, et. al., “Sources of Fatty Acids Stored in Liver and Secreted via Lipoproteins in Patients with Nonalcoholic Fatly7 Liver Disease,” J. Clin. Invest. 115 (5). 2005, 1343—-51; Lambert, J. E, et. al., “Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals with Nonalcoholic Fatty Liver Disease,” Ygast 146 (3).2014, 726—35) . The DNL pathway not only produces fatty7 acids that contribute to elevated liver stores of triglycerides, but the fatty acids that are produced are saturated fatty acid species, primarily palmitate, which contribute to signaling events that increase liver inflammation (Wei, Y., “Saturated Fatty Acids Induce Endoplasmic Reticulum Stress and Apoptosis Independently of Ceramide in Liver Cells,” Am. J. Physio. Endocrinol. Metah. 291 (2): 2006, E275-81; Kakazu, E., et al., “Hepatocytes Release Ceramide-rich Proinflammatory Extracellular Vesicles in an IRElalpha dependent manner,” Abstract 58. AASLD- The Liver Meeting, San Francisco, CA, USA, 13-17, November, 2015). One of the key enzymes in the DNL pathway7 is fatty acid synthase (FASN) which is solely responsible for synthesizing palmitate. Thus, DNL is an important pathway for therapeutic intervention to reduce the consequences associated with metabolic syndrome and N AFLD.

[0011] Inhibition of FASN has the potential to be a treatment for a wide range of diseases including cancer, viral disease, metabolic disease, NAFLD, NASH, and inflammatory diseases, (i.e., rheumatoid arthritis, gout, pulmonary fibrosis, COPD, IBD and transplant rejection). Additionally, FASN inhibition may provide therapeutic benefits in cardiovascular disease, type II 2026223382   31 Aug 2026 diabetes, and metabolic syndrome. Successful treatment of these diseases is still a highly unmet need. While there are treatments available for diabetes and cardiovascular disease, there are currently no drugs approved to treat metabolic syndrome, NAFLD, or NASH. Thus, there is a need for novel and potent small molecule inhibitors of FASN for the treatment of these diseases. SUMMARY

[0012] The present disclosure addresses the deficiencies for antiviral and anticancer treatments by providing novel heterocyclic modulators of lipid synthesis having improved antiviral and anticancer activities.

[0013] In various aspects, the present disclosure provides for compounds of Structure (I): © or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is hydrogen or Ci-6 alkyl and R' is hydrogen, Ci-6 alkyl, or absent; A is CH or N; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, -C(=O)N(R13)(R14), -(CH2)qC(==O)N(Ri3)(Ri4), CFx OCk3, or S( 0) 2R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(R13)(R14), R2 is hydrogen, halo, C1-6 alkoxy, C1-6 alkyl, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(:=O)R8, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, “S(=O)2R20, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; 2026223382   31 Aug 2026 Rn is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(Ri3Ri4), CF3, -OCF3, -S^O^Rzo, R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl, or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(RbRi4), CF3, -OCF3, -S(=O)2R20,or Rn and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Re, Rz, Rs, R9 Rio, R13, and R14 are each independently hydrogen, Ct-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(RisRj6), or -S(=0)2R2o; R15 and Rie are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino; R17 and Ris are each independently hydrogen or alkyl or can optionally join together to form a bond; 11 is 1 or 2; and m is 0 or 1.

[0014] In various aspects, the present disclosure provides for compounds of Structure (II): (II) or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is hydrogen or C1-6 alkyl and R' is hydrogen, C1-6 alkyl, or absent; L and D are each independently C or N; Ri is hydrogen, cyano, halo, C1-6 alkyl, C1-6 alkoxy, -C(=O)N(R13)(R14), -(CH2)qC(==O)N(Ri3)(Ri4), CF3, -OCF3, or S( O)'R'< q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(R13)(R14); R2 is hydrogen, halo, C1-6 alkoxy, Cj-6 alkyl, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; 2026223382   31 Aug 2026 Rs is hydrogen, hydroxyl, halo, Ci-6 alkyl, Ci-6 alkoxy, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(:=O)R8, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, ~S(=O)2R20, or Ri and Ru taken together with the atoms to which they are attached join together to form a heteroaryl; Rn is hydrogen, halo, cyano, Cns alkyl, Cns alkoxy, -N(RbR14), CFs, -OCF3, -S(=O)2R20, R4 and Ru taken together with the atoms to which they are attached join together to form a heteroaryl, or Ru and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, Cns alkyl, Cns alkoxy, -N(RbR14), CFs, -OCF3, -S(=O)2R20,or R11 and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R5, Rs, R?, Rs, R9 Rio, R13, and R14 are each independently hydrogen, Cns alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(RisR16), or -S(=0)2R2o; R15 and Ris are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino; R17 and Ris are each independently hydrogen or alkyl or can optionally join together to form a bond; n is 1 or 2; and m is 0 or 1.

[0015] In various aspects, the present disclosure provides for compounds of Structure (III): (III) or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is hydrogen or C1-6 alkyl and R' is hydrogen, C1-6 alkyl, or absent; Q is C or N; R is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or if Q is N then R? is absent; 2026223382   31 Aug 2026 R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(:=O)R8, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, -S^OJzRzo, or R4 and Ri 1 taken together with the atoms to which they are attached join together to form a heteroaryl; Rn is hydrogen, halo, cyano, Cj-6 alkyl, C1-6 alkoxy, -N(RbR14), CF3, -OCF3, -S(=O)2R20, R4 and Ru taken together with the atoms to which they are attached join together to form a heteroaryl, or Ru and Ru taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, Cj-6 alkyl, Cns alkoxy, -N(RbR14), CF3, -OCF3, -S(=O)2R20,or Ru and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(R13)(R14); Rs, Re, R7, Rs, Rs Rio, R13, and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(Ri5Rie), or -S(=0)2R2o; Ri5 and Rie are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino; Rn and Ris are each independently hydrogen or alkyl or can optionally join together to form a bond; R19 is aryl, heteroaryl, cycloalkyl, or heterocyclyl; n is 0, 1, or 2; and m is 0 or 1.

[0016] In various aspects, the present disclosure provides for compounds of Structures (IV-A), (W-B), or (IV-C): (IV-A) (IV-B) 2026223382   31 Aug 2026 R2S (IV-C) or a pharmaceutically acceptable salt thereof, wherein: Li, L2, L3, L4, and A are each independently CH or N; Ri is hydrogen, cyano, halo, Ci-s alkyl, Ci-6 alkoxy, -C(=O)N(R13)(R14), -(CH2)qC(=O)N(Ri3)(Ri4), CF3, “OCF3, or-S(=0)2R2o; q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(R13)(R14); R2 is hydrogen, halo. C1-6 alkoxy, or Ci-6 alkvl; Ra is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Ci-s alkoxy, CF3, -OCR or S( Op.R.x R23 is hydrogen, -N(R13)(R14), C1-6 alkyl, C1-6 alkoxy, is absent if Li is N, or R23 and R24 taken together with the atoms to which they are attached join together to form a heterocyclyl, heteroaryl, or cycloalkyl; R24 is hydrogen, -N(R13)(R14), C1-6 alkyl, C1-6 alkoxy, -(C1-6 alkoxy)(heterocyclyl), heterocyclyl, or R23 and R24 taken together with the atoms to which they are attached join together to form a heterocyclyl, heteroaryl, or cycloalkyl; R2.6 is hydrogen, heteroaryl, heterocyclyl, ~-N(Ri3)(Ri4), or S{ ())^R R13 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -NfRisRie), or ~S(=0)2R2o; R25 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; and R15 and Ri6 are each independently hydrogen, C1-6 alkyl, C1-6 alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[0017] In various aspects, the present disclosure provides for compounds of Structure (V): 2026223382   31 Aug 2026 (V) or a pharmaceutically acceptable salt thereof! wherein: L7 is N or O, wherein Rao is absent if L7 is O; A is CH or N; Ri is hydrogen, cyano, halo, C1-6 alkyl, Ct-6 alkoxy, -C(=O)N(Rb)(R14), ~(CH2)qC(=O)N(Ri3)(Ri4), CF3, -OCF3, or -S(=O)2R20; q is 0, 1, 2, 3, or 4; R2o is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(Ri3)(R14); R? is hydrogen, halo, C1-6 alkoxy, or C1-6 alkyl; R3 is halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, CF3, ---OCF3, or S{ 0)   : R29 and Rao are each independently hydrogen, C1-6 alkyl, C1-6 alkoxy, hydroxyalkyl, heteroaryl, heterocyclyl, -N(Ri5Ri6), -C(;=O)R46, -R4sC(:=O)R47, or R29 and R30 taken together with the atoms to which they are attached join together to form a heteroaryl or heterocyclyl, wherein R30 is absent if L7 is O; R46 and R47 are each independently hydrogen, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, -N(Ri5Ri6), or ”S(=0)2R2o; R48 is alkyl or is absent; R31 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; R13 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(RjsRj6), or -S(=0)2R2o; R15 and Rie are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; and v is 0 or 1. 2026223382   31 Aug 2026

[0018] In various aspects, the present disclosure provides for compounds of Structures (Vl-A) or (VI-B): (VI-A)                                        (VI-B) or a pharmaceutically acceptable salt thereof, wherein: Lb, Li4, Lis, and A are each independently CH or N; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, “C(=O)N(Rb)(R14), (CH'M'l=O)N(R13)(Ri4), CF3, -OCF3, or S( O)'R'< q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(Ri3)(Ri4); R> is hydrogen, halo, C1-6 alkoxy, or Ct-6 alkyl; R3 is halo, Ci-6 alkyl, or Ci-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Ci-6 alkoxy, CF3, -- OCF3, or S( O) ’R .< R34 is hydrogen, Ci-6 alkyl, Cns alkoxy, cycloalkyl, hydroxyl, hydroxyalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, CF3, -OCF3, -S(=O)2R20, or -N(Rj5Ri6); Rb is hydrogen, Ci-6 alkyl, or C1-6 alkoxy; R?6 is hydrogen, C1-6 alkyl, C1-6 alkoxy, -N(RbR16), heterocyclyl, or heteroaryl; Rd and R14 are each independently hydrogen, Cue alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(Ri5Ri6), or -S(=0)2R2o; and Ri5 and Ri6 are each independently hydrogen, Cue alkyl, Ci-s alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[0019] In various aspects, the present disclosure provides for compounds of Structure (VI-J): 2026223382   31 Aug 2026 or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ct-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is C(O)-R '5I. -C(O)-NHR351, -C(O)-O-R351 or S(ObRand R35! is Ci-Ce straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl.

[0020] In some aspects of Structure (VI-J), R3 is H or halogen.

[0021] In some aspects of Structure (VI-J), R1 is halogen, -CN or C1-C2 haloalkyl.

[0022] In some aspects of Structure (VI-J), R22 is C1-C2 alkyl.

[0023] In some aspects of Structure (VI-J), R21 is cyclobutyl and R22 is C1-C2 alkyl.

[0024] In some aspects of Structure (VI-J), R21 is cyclobutyl.

[0025] In some aspects of Structure (VI-J), R2 is H or F.

[0026] In some aspects of Structure (VI-J), R1 is -CN.

[0027] In some aspects of Structure (VI-J), R1 is -CF3.

[0028] In some aspects of Structure (VI-J), R22 is H, methyl or ethyl.

[0029] In some aspects of Structure (VI-J), R22 is H.

[0030] In some aspects of Structure (VI-J), R22 is methyl.

[0031] In some aspects of Structure (VI-J), R25 is -C(O)-NHR351. 2026223382   31 Aug 2026

[0032] In some aspects of Structure (VI-J), R35i is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahydro-2 / f-pyran-3-yl or (S)-tetrahydro-2H-pyran-3-yl.

[0033] In some aspects of Structure (VI-J), R331 is (R)-(tetrahydrofuran-2-yl)methyl or (S)-(tetrahydrofuran-2-yl)methyl.

[0034] In some aspects of Structure (VI-J), Rf is -CN, each R2 is hydrogen, R3 is H or F, R2f is C3-C4 cycloalkyl, R22 is H, R35 is ••CiOl-NHR''3’ where R35f is isopropyl, isobutyl, (R)-3-tetrahy drofuranyl, (S)-3 -tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl) methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahydro-2 / f-pyran-3-yl, or (S)-tetrahydro-2 / f-pyran-3-yl.

[0035] In some aspects of Structure (VI-J), R35 is -C(O)-O~ R351.

[0036] In some aspects of Structure (VI-J), R35i is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahy dro-2 / / -pyran-3-yl, or (S)-tetrahydro-2 / f-pyran-3-yl.

[0037] In some aspects of Structure (VI-J), R1 is -CN, each R2 is H, R3 is H or F, R21 is C3-C4 cycloalkyl, R22 is H, R35 is -CCOJ-O-R251 where R351 is isopropyl, isobutyl, (R)-3-tetrahy drofuranyl,      (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)- (tetrahydrofuran-2-yl)methyl, (R)- tetrahydro-2 / 7-pyran-3-yl, or (S)-tetrahydro-2ff-pyran-3-yl.

[0038] In some aspects of Structure (VI-J), R331 is (R)-3-tetrahydrofuranyl or (S)-3-tetrahy dr ofuranyl. 2026223382   31 Aug 2026

[0039] In some aspects of Structure (VI-J), compounds have a structure selected from the group consisting of:

[0040] In various aspects, the present disclosure provides for compounds of Structures (VII-A) or (Vn-B): (VII-B) 2026223382   31 Aug 2026 or a pharmaceutically acceptable salt thereof, wherein: Li6 is C or N, wherein R41 is absent if Lis is N; L17, Lis, and A are each independently CH or N; Ri is hydrogen, cyano, halo, Cj-6 alkyl, C1-6 alkoxy, ~C(=O)N(Rj3)(R14), -(CH2)qC(=O)N(Rn)(Ri4), CF3, -OCF3, or-S(=0)2R2o; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Ct-6 alkyl, Cns alkoxy, or -N(R13)(R14); Rz is hydrogen, halo, C1-6 alkoxy, or Ct-6 alkyl; R3 is hydrogen, hydroxyl, halo, Ci-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Cj-s alkoxy, CFs, -OCFs, or ~S(=0)2R2o; R40, R42, and R43 are each independently hydrogen, C1-6 alkyl, C1-6 alkoxy, -S(=O)2R20, -C(=O)R, hydroxyalkyl, hydroxyl, -N(R13R14), or R41 and R-n taken together with the atoms to which they are attached join together to form a heteroaryl or heterocyclyl; R41 is hydrogen, C1-6 alkyl, C1-6 alkoxy, -S(=O)2R20, -C(=O)R, hydroxyalkyl, hydroxyl, -N(Ri3Ri4), R41 is absent if Lis is N, or R41 and R42 taken together with the atoms to which they are attached join together to form a heteroaryl or heterocyclyl; R is hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, ~N(R15R16), or S(())2R20; R39 is hydrogen, Ci-s alkyl, or C1-6 alkoxy; R13 and R14 are each independently hydrogen, Cns alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(Ri5Ris), or -S(=0)2R2o; and R15 and Ris are each independently hydrogen, Cns alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino. 2026223382   31 Aug 2026

[0041] In various aspects, the present disclosure provides for compounds of Structures (VIII-A), (VIU-B), or (VIII-C): ^44-s. _z<0 or a pharmaceutically acceptable salt thereof, wherein: L19 and A are each independently CH or N; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, -C(=O)N(R13)(R14), -(CH2)qC(=O)N(Ri3)(Ri4), CF3, -OCF3, or S( O)'R'< q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(R13)(R14); R2 is hydrogen, halo, C1-6 alkoxy, or C1-6 alkyl; Rs is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, CF3, ---OCF3, or S{ OHCh; R39 is hydrogen, Ci-6 alkyl, or C1-6 alkoxy; R44 and R45 are each independently hydrogen, Cue alkyl, Ct-6 alkoxy, cycloalkyl, hydroxyalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, -S(=O)2R20, -C(=O)R, or -N(Rj3Ri4); and R13 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(RjsRj6), or -S(=0)2R2o; and 2026223382   31 Aug 2026 Ris and Ri6 are each independently hydrogen, Ci-e alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[0042] In various aspects, compounds of Structure (IX) are provided: or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L / is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl. 2026223382   31 Aug 2026

[0043] In some aspects of Structure (IX), R24 is C1-C4 straight or branched alkyl or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein t is 0 or 1.

[0044] In some aspects of Structure (IX), R21 is halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom, -S(O)u“(Ci“C4 straight or branched alkyl) wherein u is 0 or 2, or -S(O)u-( C3-C5 cycloalkyl) wherein u is 0 or 2;

[0045] In some aspects of Structure (IX), R3 is H or halogen.

[0046] In some aspects of Structure (IX), Rf is halogen, -CN or C1-C2 haloalkyl.

[0047] In some aspects of Structure (IX), both L1 and L2 are N.

[0048] In some aspects of Structure (IX), R21 is C1-C2 alkyl or C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[0049] In some aspects of Structure (IX), R21 is C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[0050] In some aspects of Structure (IX), R24 is -(C1-C2 alkyl)t-O-(Ci-C2 alkyl) wherein t is 0 or 1.

[0051] In some aspects of Structure (IX), R21 is C3-C5 cycloalkyl, R22 is C1-C2 alkyl and R24 is Ci-C2 alkyl.

[0052] In some aspects of Structure (IX), R21 is cyclobutyl, R22 is C1-C2 alkyl and R24 is C1-C2 alkyl.

[0053] In some aspects of Structure (IX), R21 is cyclobutyl.

[0054] In some aspects of Structure (IX), R' is II or F.

[0055] In some aspects of Structure (IX), R1 is -CN.

[0056] In some aspects of Structure (IX), R1 is -CF3.

[0057] In some aspects of Structure (IX), R22 is H, methyl or ethyl.

[0058] In some aspects of Structure (IX), R22 is H.

[0059] In some aspects of Structure (IX), R22 is methyl.

[0060] In some aspects of Structure (IX), R1 is -CN, each R2 is H, R5 is H or F, R21 is C3-C4 cycloalkyl, R22 is methyl, L1 and L2 are N, and R24 is methyl, ethyl, hydroxymethyl, methoxymethyl, 2-methoxyethyl.

[0061] In some aspects of Structure (IX), R1 is ---CN, each R2 is H, R2 is H or F, R21 is C3-C4 cycloalkyl, R22 is methyl, L1 and L2 are N, and R24 is methoxy or ethoxy. 2026223382   31 Aug 2026

[0062] In some aspects of Structure (IX), R1 is -CN, each R2 is H, R5 is H or F, R21 is C3-C4 cycloalkyl, R22 is methyl, L1 is CH, L2 is N, and R24 is methyl, ethyl, hydroxymethyl, methoxymethyl, or 2-methoxyethyl.

[0063] In some aspects of Structure (IX), R1 is -CN, each R2 is H, R2 is H or F, R21 is C3-C4 cycloalkyl, R22 is methyl, L! is N, L2 is CH, and R24 is methyl, ethyl, hydroxymethyl, methoxymethyl, or 2-methoxyethyl.

[0064] In some aspects of Structure (IX), compounds have a structure selected from the group consisting of: —n   N-m      n                         N-n      n

[0065] In various aspects, compounds of Structure (X) are provided: or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; 2026223382   31 Aug 2026 R3 is H, -OH or halogen; L3 is C(R60)2, O or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-Cs cycloalkyl), -O-fCi-O straight or branched alkyl), or -C(O)-N(R60!)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ct-C4 straight or branched alkyl), -C(O)-Ot-(Cs-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R’01)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), --C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50i)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R6ul and R "H is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R50, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R501 and R601 may be two R26, two R60, two R50, two R50! or two R601.

[0066] In some aspects of Structure (X), R21 is halogen, C1-C4 straight or branched alkyl or C3-C5 cycloalkyl.

[0067] In some aspects of Structure (X), R3 is II or halogen.

[0068] In some aspects of Structure (X), Rf is -CN or C1-C2 haloalky!.

[0069] In some aspects of Structure (X), R3 is II or E

[0070] In some aspects of Structure (X), Rf is -CN. 2026223382   31 Aug 2026

[0071] In some aspects of Structure (X), R11S-CF3.

[0072] In some aspects of Structure (X), n is 1.

[0073] In some aspects of Structure (X), n is 2.

[0074] In some aspects of Structure (X), m is 1

[0075] In some aspects of Structure (X), m is 2.

[0076] In some aspects of Structure (X), R21 is C1-C2 alkyl or C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[0077] In some aspects of Structure (X), R2f is C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[0078] In some aspects of Structure (X), n is 2, m is 1,I? is -N-C(O)-O-(Ci-C2 alkyl).

[0079] In some aspects of Structure (X), L3 is NR50; R50 is C1-C2 alkyl; R21 is cyclobutyl; R22 is H or methyl; R3 is H; R1 is -CN; m is 2 and n is 1 or 2.

[0080] In some aspects of Structure (X), n is 2, m is 1,IF is O and s is 0.

[0081] In some aspects of Structure (X), R22 is H, methyl or ethyl.

[0082] In some aspects of Structure (X), R22 is methyl.

[0083] In some aspects of Structure (X), R22 is H.

[0084] In some aspects of Structure (X), R1 is ~CN, each R2 is H, R3 is H or F, R21 is C3-C4 cycloalkyl, Rzz is methyl, n is 2 and L3 is NR50 where R50 is methyl or ethyl.

[0085] In some aspects of Structure (X), R1 is ~CN, each R2 is H, R3 is H or F, R21 is C3-C4 cycloalkyl, Rzz is methyl, n is 2 and L3 is O.

[0086] In some aspects of Structure (X), the compound has a structure selected from the group consisting of

[0087] In various aspects, compounds of Structure (XI) are provided: 2026223382   31 Aug 2026 O 0 or a pharmaceutically acceptable salt thereof, wherein: R'1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(Cs-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R331 is C1-C2 alkyl or C2-O-(Cj or C2 alkyl).

[0088] In some aspects of Structure (XI), R3 is H or halogen.

[0089] In some aspects of Structure (XI), R1 is halogen, -CN or C1-C2 haloalkyl.

[0090] In some aspects of Structure (XI), R21 is C3-C4 cycloalkyl and R22 is C1-C2 alkyl.

[0091] In some aspects of Structure (XI), R21 is cyclobutyl and R22 is C1-C2 alkyl.

[0092] In some aspects of Structure (XI), R21 is cyclobutyl.

[0093] In some aspects of Structure (XI), R3 is H or F.

[0094] In some aspects of Structure (XI), R1 is -CN.

[0095] In some aspects of Structure (XI), R1 is -CF3.

[0096] In some aspects of Structure (XI), R22 is H, methyl or ethyl.

[0097] In some aspects of Structure (XI), R22 is H.

[0098] In some aspects of Structure (XI), R22 is methyl.

[0099] In some aspects of Structure (XI), R1 is -CN, each R2 is H, R3 is II or F, R21 is cyclobutyl, R22 is methyl and R351 is methyl or ethyl.

[00100] In some aspects of Structure (XI), the compound has a structure selected from the group consisting of: 2026223382   31 Aug 2026

[00101] In various aspects, the present disclosure provides pharmaceutical compositions comprising any one of the compounds of Structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) or (XI) and a pharmaceutically acceptable carrier, excipient, or diluent.

[00102] In various aspects, the present disclosure provides methods of treating a condition characterized by disregulation of a fatty acid synthase function in subject, the method comprising administering to the subject in need of such treatment an effective amount of a compound of any one of the Structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) or (XI). In various aspects the condition characterized by disregulation of the fatty acid synthase function is a viral infection or cancer. In various aspects the viral infection is treated using a compound of any one of the Structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) or (XI) in combination with one or more additional antiviral treatments. In various aspects the cancer is treated using a compound of any one of the Structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) or (XI) in combination with one or more additional cancer treatments. In various aspects, the viral infection is hepatitis C.

[00103] In various aspects, the present disclosure relates to a method of treating fatty liver disease in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) R2 (IX), or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R'1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(Cs-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; IJ is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R2j is H or C1-C4 straight or branched alkyl; or (b) Formula (X): R2 (X), or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and 2026223382   31 Aug 2026 when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R’ is H, -OH or halogen; L3 is C(R60)2, 0 or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R60!)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ct-C4 straight or branched alkyl), -C(O)-Ot-(Cs-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R501)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), ---C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50i)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R6u1 and R"2 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R50, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R501 and R601 may be two R26, two R60, two R50, two R503 or two R603; or (c) Formula (VI-J) 2026223382   31 Aug 2026 or a pharmaceutically acceptable salt thereof, wherein: R'1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(Cs-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or SfOhR353; and R351 is Ci-Ce straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 Het is a 5- to 6-membered heteroaryl; Rs is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, Rl is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)-N(Rz41)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each Rz41 is independently H or C1-C2 alkyl; and R25 is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R25 is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C.i alkyl)-OH, -(C1-C4 alkyl)-N(R24i)2, -((4-(4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl>Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl>-N(R24l)2, -(C1-C4 alkyl)t-Ot-(C3-Cs cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): or pharmaceutically acceptable salts thereof, wherein: L3 is -CH2-, -CHR50-, -()-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-Q alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; 2026223382   31 Aug 2026 Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R' is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): or pharmaceutically acceptable salts thereof, wherein: * R“ |—bZ"'! R3 <. / \ R3 N^^—Ar ® 'V'-'N            X”Ar L-Ar is Xz ,            Ar or \'      -, 2026223382   31 Aug 2026 Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R25 is independently H, -C1-C4 alkyl, or halogen; or (i) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 R2 R2 Het is a 5- to 6-membered heteroaryl; Rs is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R ’ is H or F; R11 is FI or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(Cj-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(Cj-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and R24i is H or C1-C2 alkyl; or (j) Formula (XVIII): O is X Ar or pharmaceutically acceptable salts thereof, wherein: 1..... L-Ar is 5          ,         Ar or    X— /    ; 2026223382   31 Aug 2026 QR“ -Ar .           .                                                 , Ar is not L2 is -NHR35 or -C(O)NHR?’1, wherein R351 is Ci-Cc, alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when Rl is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R35 is -C(O)R351, -C(O)NHR351, C(O)OR351 or S(O)2R351 wherein R351 is Ci-Ce alkyl, C3-Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR26- with the proviso that not more than 2 of W, X, Y and Z are -N-; each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R2 / )2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); 2026223382   31 Aug 2026 each R27 is independently H or C1-C4 alkyl or both R27 are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R' is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R'1 is H, -CN, halogen, C1-C4 alkyl, -O-(Cs-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R’ is H or F; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -O-(Ci-C4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-Cs cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R23 is H, halogen, C1-C4 alkyl or Cs-Cs cycloalkyl, wherein R23 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -0-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R' is independently H, halogen or C1-C4 straight or branched alkyl; R’ is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R35i is CJ-C2 alkyl or C2-O-(Ct or C2 alkyl).

[00104] In various aspects, the present disclosure relates to a method of treating nonalcoholic steatohepatitis (NASH) in a subject in need thereof) the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: 2026223382   31 Aug 2026 (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O~(Cj-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2’1 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 aIkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl; or (b) Formula (X): 2026223382   31 Aug 2026 or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ct-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(R60)2, 0 or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R5" is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R501)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1,2 or 3; m is 1 or 2; R2'1 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -((1-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 R2 R2 or R2. each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2, is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Ar is R2 Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): R24     ,- p;2o O N II 'hr H R: Ar R22    (XX), or a pharmaceutically acceptable salt thereof, wherein: L-Ar is R3 N Lr3 —Ar     —'x .           Ar or ,R3 ~Ar 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00105] In various aspects, the present disclosure relates to a method of treating nonalcoholic fatty liver disease (NAFLD) in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when Rl is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; RJ is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR2 3 or N; L2 is CH or N; at least one of L1 or L2 is N; and R2-’ is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(O or NR50; each R°° is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R24f is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof, wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 R2 \ N                                                                             ., \ J                               1  1--\zR N-^ 2                           |-N K-Ar ;y /       , with the proviso that when L-Ar is    \—'     , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: . Z\ HnZ^Lr3 &  / ““XX L-Ar is 5          ,         Ar or    X— /    ; 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00106] In various aspects, the present disclosure relates to a method of treating metabolic syndrome in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, Ci-Cr straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or I; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R2' is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(Cs-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when Rl is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; RJ is H, -OH or halogen; L3 is C(R6O)2, 0 or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -~C(0)-0t-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently ---OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), ---C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R50f is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R50, R30! and R60' optionally join to form a ring wherein the two of R26, R60, R50, R501 and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: |\-"x       N V~Ar L-Aris                    Ar or    \— / r2 Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 R2 R2 or R2. each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2, is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Ar is R2 Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): R24     ,- p;2o O N II 'hr H R: Ar R22    (XX), or a pharmaceutically acceptable salt thereof, wherein: L-Ar is R3 N Lr3 —Ar     —'x .           Ar or ,R3 ~Ar 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00107] In various aspects, the present disclosure relates to a method of treating liver cirrhosis in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(O or NR50; each R°° is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R351 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00108] In various aspects, the present disclosure relates to a method of treating liver fibrosis in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(O or NR50; each R°° is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: . Z\ HnZ^Lr3 &  / ““XX L-Ar is 5          ,         Ar or    X— /    ; 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00109] In various aspects, the present disclosure relates to a method of treating liver cancer in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(O or NR50; each R°° is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-(4 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(14: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -((1-(4 alkyl)t-Ot-(C3-Cs cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -((^-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00110] In various aspects, the present disclosure relates to a method of treating a disease or condition in which interleukin 1 beta (ILIp) levels are elevated in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) -          (IX), or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R' is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH -(C1-C4 alkyl)t-Ot-(C3-Cs cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and 2026223382   31 Aug 2026 R23 is H or C1-C4 straight or branched alkyl; or (b) Formula (X): R2 (X), or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(R60)2, 0 or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R5" is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R501)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R2'1 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom 2026223382   31 Aug 2026 R22 is H, halogen, C1-C2 alkyl; each R26 is independently OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(Cs-C5 cycloalkyl), -(C1-C4 alkyl)t-0-(Ci-C4 straight or branched alkyl), -C(O)“Ot~(Ci-C4 alkyl), or -C(O)-N(R50!)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R301 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R50, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R501 and R601 may be two R26, two R60, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-fCs-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R35i; and R35! is Ci-Ce straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 R25 N—- /      O r24-4 I      JI H J| I Ar R21,Jx^^R22   (XH). or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R23 is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or 2026223382   31 Aug 2026 (e) Formula (XIII): Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not FI, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is FI or F; R11 is H or -CH3; R2'1 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R25 is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alky O-XiR241 )2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or Cj-Ca alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00111] In various aspects, the present disclosure relates to a method of treating a disease or condition in which t-helper (Th) cell levels are elevated in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) R2 (IX), or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L! is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and 2026223382   31 Aug 2026 R23 is H or C1-C4 straight or branched alkyl; or (b) Formula (X): R2 (X), or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(R60)2, 0 or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R5" is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R501)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R2'1 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom 2026223382   31 Aug 2026 R22 is H, halogen, C1-C2 alkyl; each R26 is independently OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(Cs-C5 cycloalkyl), -(C1-C4 alkyl)t-0-(Ci-C4 straight or branched alkyl), -C(O)“Ot~(Ci-C4 alkyl), or -C(O)-N(R50!)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R301 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R50, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R501 and R601 may be two R26, two R60, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-fCs-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R35i; and R35! is Ci-Ce straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 R25 N—- /      O r24-4 I      JI H J| I Ar R21,Jx^^R22   (XH). or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R23 is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or 2026223382   31 Aug 2026 (e) Formula (XIII): Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not FI, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is FI or F; R11 is H or -CH3; R2'1 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R25 is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alky B-XfR241 )2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or Cj-Ca alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00112] In various aspects, the present disclosure relates to a method of treating a disease or condition in which regulatory t cells (Treg) are reduced or suppressed in a subject in need thereof, the method comprising administering to the subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) R2 (IX), or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L! is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and 2026223382   31 Aug 2026 R23 is H or C1-C4 straight or branched alkyl; or (b) Formula (X): R2 (X), or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(R60)2, 0 or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R5" is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R501)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R2'1 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom 2026223382   31 Aug 2026 R22 is H, halogen, C1-C2 alkyl; each R26 is independently OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(Cs-C5 cycloalkyl), -(C1-C4 alkyl)t-0-(Ci-C4 straight or branched alkyl), -C(O)“Ot~(Ci-C4 alkyl), or -C(O)-N(R50!)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R301 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R50, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R501 and R601 may be two R26, two R60, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-fCs-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R35i; and R35! is Ci-Ce straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 R25 N—- /      O r24-4 I      JI H J| I Ar R^'^^'^^'R22    (XH). or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R23 is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or 2026223382   31 Aug 2026 (e) Formula (XIII): Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not FI, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is FI or F; R11 is H or -CH3; R2'1 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R25 is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alky B-XfR241 )2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or Cj-Ca alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 R2 R2 or R2. each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2, is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Ar is R2 Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): R24     ,- p;2o O N II 'hr H R: Ar R22    (XX), or a pharmaceutically acceptable salt thereof, wherein: L-Ar is R3 N Lr3 —Ar     —'x .           Ar or ,R3 ~Ar 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00113] In various aspects, the present disclosure relates to a method of reversing established non-alcoholic steatohepatitis (NASH), the method comprising administering to a subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(O or NR50; each R°° is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00114] In various aspects, the present disclosure relates to a method of reducing fibrotic gene expression, the method comprising administering to a subject in need thereof a fatty acid synthase inhibitor having a formula of (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(O or NR50; each R°° is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -((1-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00115] In various aspects, the present disclosure relates to a method of treating skin fibrosis, the method comprising administering to a subject in need thereof a fatty acid synthase inhibitor having a formula of: (a) Formula (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L1 is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl; or 2026223382   31 Aug 2026 (b) Formula (X): or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(O or NR50; each R°° is independently H, -OH, -CN, -Ot-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R601)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-C5 cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R5ul)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; 2026223382   31 Aug 2026 each R26 is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(Ci-C4 alkyl), or -C(O)-N(R50f)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R00, two R50, two R501 or two R601; or (c) Formula (VI-J) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R3si is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; or (d) Formula (XII): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; Rn is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is FI, halogen, or C1-C2 alkyl; R24 is H, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(C1-C4 alkyi)-OH -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C6 cycloalkyl), -(C1-C4 alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1; u is 0 or 1; with the proviso that when u is 1, t is 1; and each R241 is independently H or C1-C2 alkyl; and R2’ is halogen, -CN, -(C1-C4 alkyl)-CN, C1-C2 alkyl or cyclopropyl; or (e) Formula (XIII): 2026223382   31 Aug 2026 »24 or pharmaceutically acceptable salts thereof, wherein: L-Ar is Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each R24 and R2’ is independently H, halogen, -CN, -(C1-C4 alkyl)-CN, C1-C4 alkyl, -(Ci-C4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; each u is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (f) Formula (XIV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -0-((4-05 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -(16: R2'1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)t-N(R24!)2, -(0:-(4 alkyl)t-Ot-(C3-C5 cycloalkyl), -(C1-C4 alkyl)t-0t-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)t-O-(Ci-C4 alkyl), wherein: each t is independently 0 or 1; and each R241 is independently H or C1-C2 alkyl; or (g) Formula (XV): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: L3 is -CH?-, -CHR50-, -0-, -NR50-, -NC(O)R50- or -NC(O)OR50-, wherein R50 is Ci-C6 alkyl, C3-C5 cycloalkyl, or 4- to 6-membered heterocycle; n is 1, 2, or 3; m is 1 or 2 with the proviso that n+m > 3; Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen, or C1-C2 alkyl; or (h) Formula (XVI): 2026223382   31 Aug 2026 or pharmaceutically acceptable salts thereof, wherein: Het is a 5- to 6-membered heteroaryl; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-C5 cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CHy R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and each of R24 and R2’ is independently H, -C1-C4 alkyl, or halogen; or (1) Formula (XVII): or pharmaceutically acceptable salts thereof, wherein: 2026223382   31 Aug 2026 with the proviso that when L-Ar is R3 -Ar , Ar is not Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when Rs is not H. -CN or halogen, R! is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R; is H or F; R11 is H or -CH3; R21 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; and R24 is H, C1-C4 alkyl, -(0-(4 alkyl)-OH, -(C1-C4 alkyl)-N(R241)2, -(C1-C4 alkyl)t-Ou-(C3 Cs cycloalkyl), -(Cj-Q alkyl) t-Ou-(4- to 6-membered heterocycle) or -(C1-C4 alkyl)-O-(Ci-C4 alkyl), wherein: t is 0 or 1: u is 0 or 1; with the proviso that when u is 1, t is 1; and R241 is H or C1-C2 alkyl; or (j) Formula (XVIII): O 'Ar (xvni), or pharmaceutically acceptable salts thereof) wherein: „R3 'Ar or -Ar 2026223382   31 Aug 2026 R2 R2 with the proviso that when L-Ar is , Ar is not L2 is -NHR35 or -C(O)NHR351, wherein R35i is Ci-Ce alkyl, C3-C5 cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; Het is a 5- to 6-membered heteroaryl; R'1 is H, -CN, halogen, C1-C4 alkyl, -0-(0-(15 cycloalkyl), -0-(4- to 6-membered heterocycle), -O-(Ci-C4 alkyl) wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R11 is H or -CH3; R2! is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen, or C1-C2 alkyl; and R33 is -C(O)R351, -C^NHR531, C(O)OR35J or S(O)2Rj5f wherein R331 is Ci-Cei alkyl, C3- Cs cycloalkyl, 4- to 6- membered heterocycle, aryl or heteroaryl; or (k) Formula (XIX): or pharmaceutically acceptable salts thereof, wherein: each W, X, Y and Z is independently -N- or -CR2b- with the proviso that not more than 2 of W, X, Y and Z are -N-; 2026223382   31 Aug 2026 each R26 is independently H, C1-C4 alkyl, -O-(Ci-C4 alkyl), -N(R27)2, -S(O)2-(Ci-C4 alkyl), or -C(O)-(Ci-C4 alkyl); each R2' is independently H or C1-C4 alkyl or both R2 / are C1-C4 alkyl and join to form a 3- to 6-membered ring together with the N to which they are attached and wherein the ring optionally includes one oxygen atom as one of the members of the ring; Het is a 5- to 6-membered heteroaryl; R! is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle), -0-(Cj~C4 alkyl) wherein when R! is not H, -CN or halogen, R1 is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R“ is H or -CH3; R2’1 is H, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or a 4- to 6-membered heterocycle; and R22 is H, halogen or C1-C2 alkyl; or (1) Formula (XX): or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R2 Ar is R2 ; R1 is H, -CN, halogen, C1-C4 alkyl, -O-(C3-Cs cycloalkyl), -0-(4- to 6-membered heterocycle) or -O-(Ci-C4 alkyl), wherein when R1 is not H, -CN or halogen, R1 is optionally substituted with one or more halogen; each Rz is independently hydrogen, halogen or C1-C4 alkyl; R3 is H or F; R21 is FI, halogen, C1-C4 alkyl, C3-C5 cycloalkyl or 4- to 6-membered heterocycle; R22 is H, halogen or C1-C2 alkyl; R24 is -O-(Ci-C4 alkyl), -0-((4-(4 alkyl)-O-(Ci-C4 alkyl), -O-(C3-C5 cycloalkyl), or -O-(4- to 6-membered heterocycle), wherein R24 is optionally substituted with one or more hydroxyl or halogen; and R25 is H, halogen, C1-C4 alkyl or C3-C5 cycloalkyl, wherein R25 is optionally substituted with one or more halogen; or (m) Formula (XI): O O or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R3’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl). 2026223382   31 Aug 2026

[00116] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating non-alcoholic steatohepatitis (NASH) or symptoms of NASH. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for treating non-alcoholic steatohepatitis (NASH) or symptoms of NASH.

[00117] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating non-alcoholic fatty liver disease (NAFLD). In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for treating non-alcoholic fatty liver disease (NAFLD).

[00118] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VH), {VIH). (IX), (X), (XI) or as provided m Table 1 can be used for the manufacture of a medicament for treating metabolic syndrome. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VH), (VIH), (IX), (X), (XI) or as provided in Table 1 can be used for treating metabolic syndrome.

[00119] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VH), (VIH), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating liver cirrhosis. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII ). (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for treating liver cirrhosis.

[00120] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating liver fibrosis. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for treating liver fibrosis.

[00121] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating liver cancer. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for treating liver cancer.

[00122] In various aspects, compounds having Structure (I), (II), (III), (TV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament 2026223382   31 Aug 2026 for treating liver fibrosis. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for treating liver fibrosis.

[00123] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating a disease or condition in which interleukin 1 beta (IL1P) levels are elevated. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIH), (IX), (X), (XI) or as provided in Table 1 can be used for treating a disease or condition in which interleukin 1 beta (ILip) levels are elevated.

[00124] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating a disease or condition in which t~helper (Th) cell levels are elevated. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VH), (VIII), (IX), (X), (XI) or as provided m Table 1 can be used for treating a disease or condition in which t-helper (Th) cell levels are elevated.

[00125] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VH), (Vm), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating a disease or condition in which regulatory t cells (Treg) are reduced or suppressed. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (XT), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for a disease or condition in which regulatory t cells (Treg) are reduced or suppressed.

[00126] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VH), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating or reversing established non-alcoholic steatohepatitis (NASH). In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table I can be used for treating or reversing established non-alcoholic steatohepatitis (NASH).

[00127] In various aspects, compounds having Structure (I), (II), (III), (TV), (V), (VI), (ATI), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for reducing fibrotic gene expression. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for reducing fibrotic gene expression. 2026223382   31 Aug 2026

[00128] In various aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for the manufacture of a medicament for treating skin fibrosis. In further aspects, compounds having Structure (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) or as provided in Table 1 can be used for treating skin fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[00129] FIG. 1 illustrates a correlation between FASN inhibition and HCV inhibition.

[00130] FIG. 2 shows images of liver tissue samples stained with Oil red O or Masson’s taken from C57BL / 6NCrSim mice treated with vehicle or 10 mg / kg of Compound 364.A. The results show that treatment with FASN inhibitor Compound 364A inhibited the development of steatosis.

[00131] FIG. 3 shows images of liver tissue samples stained with Oil red O taken from C57BL / 6J mice treated with vehicle for 28 days, vehicle for 57 days or vehicle for 28 days followed by 10 mg / kg Compound 364A for 29 days. The results show that treatment with FASN inhibitor Compound 364A inhibited the development of hepatic steatosis.

[00132] FIG. 4 is a graph showing IL-Ip levels in untreated rats and in rats treated with vehicle, 60 mg / kg of Compound 6B, or 100 mg / kg of Compound 6B. The results show that treatment with Compound 6B lowered IL-Ip beta levels in blood serum after feeding fasted rats.

[00133] FIG. 5 is a graph showing IL-ip levels in rats treated with vehicle, 60 mg / kg of Compound 6B, or 100 mg / kg of Compound 6B. The results show that treatment with Compound 6B lowered IL-lp beta levels in blood serum 22 hours after feeding fasted rats.

[00134] FIG. 6A is a graph showing IL-lp levels in mice fed a high fat diet for 14 days and then treated with vehicle, 3 mg / kg of Compound 364A, or 10 mg / kg of Compound 364A. FIG. 6B is a graph showing IL-lp levels in mice fed a high fat diet for 37 days and then treated with vehicle, 3 mg / kg of Compound 364A, or 10 mg / kg of Compound 364A. Mice treated with Compound 364A had reduced levels ofIL-1 beta at both 14 and 37 days, both before reintroduction of food and after feeding, compared to mice which received vehicle.

[00135] FIG. 7A. is a graph showing secretion of IL-1 p levels from human PBMC without stimulation or after 24 hours of stimulation with lipopolysaccharide (LPS) or lipoteichoic acid (LTA) when treated with vehicle or with 10 uM of Compound 242A. FIG. 7B is a graph showing secretion of IL-lp levels from human monocytes without stimulation or after 24 hours of 2026223382   31 Aug 2026 stimulation with lipopolysaccharide (LPS) or lipoteichoic acid (LTA) when treated with vehicle or with 10 pM of Compound 242A. For monocytes, Compound 242A treatment reduced the level of IL-1 beta resulting from LTA stimulation whereas only a slight reduction was observed after LPS stimulation. For PBMC, Compound 242A treatment reduced the level of IL-1 beta resulting from both LTA and LPS stimulation.

[00136] FIGs. 8A and 8B are plots showing the results of flow cytometry analysis of mouse T cells treated with vehicle (DMSO) or 50 nM of Compound 364A. FASN inhibition of mouse CD4+ naive T cells with 4 days of Thn differentiation conditions inhibits Thi7 cell differentiation and stimulates Treg differentiation.

[00137] FIGs. 9A and 9B are plots showing the results of flow cytometry analy sis of human T cells from Donor 1 treated with vehicle (DMSO) or 50 nM of Compound 364.A. FIGs. 9C and 9D are plots showing the results of flow cytometry analysis of human T cells from Donor 2 treated with vehicle (DMSO) or 50 nM of Compound 364A. FASN inhibition with Compound 364A of human CD4+ naive T cells from two different donors with 4 days of Thn differentiation conditions inhibits TH17 cell differentiation and stimulates Treg differentiation.

[00138] FIGs. 10A and 10B are plots showing the results of flow cytometry analysis of human T cells from Donor 1 treated with vehicle (DMSO) or 50 nM of Compound 152. FIGs. 10C and 10D are plots showing the results of flow cytometry analysis of human T cells from Donor 2 treated with vehicle (DMSO) or 50 nM of Compound 152. FASN inhibition with Compound 152 of human CD4+ naive T cells from two different donors with 4 days of Thn differentiation conditions inhibits TH17 cell differentiation and stimulates Treg differentiation.

[00139] FIG. 11 is a schematic of the study design and dose groups for Compound 364A and pirfenidone in Example 10.

[00140] Fig. 12A is a plot of plasma alanine aminotransferase (ALT) as a function of treatment with Compound 364A and / or pirfenidone. FIG. 12B is a plot of plasma aspartate aminotransferase (AST) as a function of treatment with Compound 3 64A and / or pirfenidone. FIG. 12C is a plot of plasma total cholesterol (TC) as a function of treatment with Compound 364A and / or pirfenidone.

[00141] FIG. 13 A is a plot of liver triglycerides as a function of treatment with Compound 364A and / or pirfenidone. FIG. 13B is a plot of liver cholesterol as a function of treatment with Compound 364A and / or pirfenidone. 2026223382   31 Aug 2026

[00142] FIG. 14A is a plot of the change in liver steatosis after dosing with vehicle (control). FIG. I4B is a plot of the change in liver steatosis after dosing with Compound 364A. FIG. 14C is a plot of the change in liver steatosis after dosing with pirfenidone. FIG. 14D is a plot of the change in liver steatosis after dosing with Compound 364A and pirfenidone.

[00143] FIG. 15A is a plot of the change in liver inflammation after dosing with vehicle (control). FIG. 15B is a plot of the change in liver inflammation after dosing with Compound 364A. FIG. 15C is a plot of the change in liver inflammation after dosing with pirfenidone. FIG. 15D is a plot of the change in liver inflammation after dosing with Compound 3 64A and pirfenidone.

[00144] FIG. 16A is a plot of the change in liver ballooning after dosing with vehicle (control). FIG. 16B is a plot of the change in liver ballooning after dosing with Compound 364A. FIG. 16C is a plot of the change in liver ballooning after dosing with pirfenidone. FIG. 16D is a plot of the change in liver ballooning after dosing with Compound 364A and pirfenidone.

[00145] FIG. 17A is a plot of the change in liver fibrosis after dosing with vehicle (control). FIG. 17B is a plot of the change in liver fibrosis after dosing with Compound 364A. FIG. 17C is a plot of the change in liver fibrosis after dosing with pirfenidone. FIG. 17D is a plot of the change in liver fibrosis after dosing with Compound 3 64A and pirfenidone.

[00146] FIG. 18A is a plot of the change in liver NAFLD activity score (NAS) after dosing with vehicle (control), FIG. 1 8B is a plot of the change in liver NAFLD activity score (NAS) after dosing with Compound 364A. FIG. 18C is a plot of the change in liver NAFLD activity score (NAS) after dosing with pirfenidone. FIG. 18D is a plot of the change in liver NAFLD activity score (NAS) after dosing with Compound 364A and pirfenidone.

[00147] FIG 19 is a plot of the change in liver collagen gene expression after dosing with vehicle (control), Compound 364A, pirfenidone, or Compound 364A and pirfenidone.

[00148] FIG 20 is a 2-D plot of the change in liver collagen gene expression by gene analysis of liver biopsies after dosing with vehicle (control), Compound 364A, pirfenidone, or Compound 3 64.A and pirfenidone.

[00149] FIG. 21 is a schematic of the study design and dose groups in Example 11.

[00150] FIG. 22 is a plot of the change in skin collagen content in the mice as a function of the dose of Compound 364A in Example II. 2026223382   31 Aug 2026

[00151] FIG. 23 shows the relative mRNA expression of fibrotic genes in immortalized human hepatic stellate cells (LX-2 cells) after treatment with Compound 364A or sorafenib. FIG. 23.A is a plot of the mRNA expression of Col lai. FIG. 23B is a plot of the mRNA expression of aSMA. FIG. 23C is a plot of the mRNA expression of PPDGFR FIG. 23D is a plot of the mRNA expression of TGFbRl. FIG. 23E is a plot of the mRN A expression of HMP1. FIG. 23F is a plot of the mRNA expression of IIMP2. FIG. 23G is a plot of the mRNA expression of MMP2. DETAILED DESCRIPTION

[00152] The present disclosure addresses the deficiencies in treating conditions characterized by disregulation of the FASN function in a subject, such as viral infection, cancer and metabolic disorders, by providing novel heterocyclic modulators of lipid synthesis.

[00153] In certain aspects, the present disclosure provides compositions and methods for treatment of viral infections. In general, the compositions and methods for treatment of viral infections are directed toward modulation of the fatty acid synthesis pathway. The fatty acid synthesis pathway is involved in the replication of viruses into the host cells. The present invention embodies methods for the treatment of viral infection, such as hepatitis C infections, yellow fever infections, and human rhinovirus infections, or any virus that targets the fatty acid synthesis pathway.

[00154] In certain aspects, the present disclosure provides compositions and methods for the treatment of cancer. Fatty acid synthase is responsible for conversion of malonyl-CoA into long-chain fatty acids, which is an early reaction in fatty acid biosynthesis. Fatty acid synthase is overexpressed in many cancer cells. Without being bound by any particular theory, it is hypothesized that inhibition of fatty acid synthase expression or fatty acid synthase activity selectivity suppresses proliferation and induces cell death of cancer cells, with little toxicity towards normal cells.

[00155] Further, the present disclosure provides compounds and methods for modulating host cell targets that are targeted by viruses. Such modulation of host cell targets can include either activation or inhibition of the host cell targets. Accordingly, compounds that modulate, e.g., inhibit, the activity of a non-viral protein, e.g., a host cell protein, e.g., components of the fatty acid synthesis pathway, can be used as antiviral pharmaceutical agents. 2026223382   31 Aug 2026 Definitions

[00156] Chemical moieties referred to as univalent chemical moieties (e.g., alkyl, aryl, etc.) also encompass structurally permissible multivalent moieties, as understood by those skilled in the art. For example, while an “alkyl” moiety generally refers to a monovalent radical (e.g., CH •( H -in appropriate circumstances an “alkyl” moiety can also refer to a divalent radical (e.g., -CH2CH2-, which is equivalent to an “alkylene” group). Similarly, under circumstances where a divalent moiety is required, those skilled in the art will understand that the term “aryl” refers to the corresponding divalent arylene group.

[00157] All atoms are understood to have their normal number of valences for bond formation (e.g., 4 for carbon, 3 for N, 2 for O, and 2, 4, or 6 for S, depending on the atom’s oxidation state). On occasion a moiety can be defined, for example, as (A)aB, wherein a is 0 or 1. In such instances, when a is 0 the moiety is B and when a is 1 the moiety is AB.

[00158] Where a substituent can vary in the number of atoms or groups of the same kind (e.g., alkyl groups can be Ci, C2, Cy etc.), the number of repeated atoms or groups can be represented by a range (e.g., Cj-Ce alkyl) which includes each and every number in the range and any and all sub ranges. For example, C1-C3 alkyl includes Ci, C2, C3, C1-2, C1-3, and C2-3 alkyl.

[00159] “Alkanoyl” refers to a carbonyl group with a lower alkyl group as a substituent.

[00160] “Alkylamino” refers to an amino group substituted by an alkyl group.

[00161] “Alkoxy” refers to an O-atom substituted by an alkyl group as defined herein, for example, methoxy [-OCH3, a Cialkoxy]. The term “C1-6 alkoxy” encompasses Ci alkoxy, C2 alkoxy, C3 alkoxy, C4 alkoxy, Cs alkoxy, Ce alkoxy, and any sub-range thereof.

[00162] “Alkoxycarbonyl” refers to a carbonyl group with an alkoxy group as a substituent.

[00163] “Alkyl,” “alkenyl,” and “alkynyl,” refer to optionally substituted, straight and branched chain aliphatic groups having from 1 to 30 carbon atoms, or preferably from 1 to 15 carbon atoms, or more preferably from 1 to 6 carbon atoms. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, vinyl, allyl, isobutenyl, ethynyl, and propynyl. The term “heteroalkyl” as used herein contemplates an alkyl with one or more heteroatoms.

[00164] “Alkylene” refers to an optionally substituted divalent radical which is a branched or unbranched hydrocarbon fragment containing the specified number of carbon atoms, and having two points of attachment. An example is propylene [--CH2CH2CH2--, a Qalkylene], 2026223382   31 Aug 2026

[00165] “.Amino” refers to the group -NH2.

[00166] “Aryl” refers to optionally substituted aromatic groups which have at least one ring having a conjugated pi electron system and includes carbocyclic aryl, and biaryl groups, all of which can be optionally substituted. Phenyl and naphthyl groups are preferred carbocyclic aryl groups.

[00167] “Aralkyl” or “arylalkyl” refer to alkyl-substituted aryl groups. Examples of aralkyl groups include butylphenyl, propylphenyl, ethylphenyl, methylphenyl, 3,5-dimethylphenyl, tertbutylphenyl. O

[00168] “Carbamoyl” as used herein contemplates a group of the structure.............C~™~NRn2 where in RN is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to C12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, sulfonyl, sulfonate and sulfonamide. O

[00169] “Carbonyl” refers to a group of the structure c .

[00170] “Cycloalkyl” refers to an optionally substituted ring, which can be saturated or unsaturated and monocyclic, bicyclic, or tricyclic formed entirely from carbon atoms. An example of a cycloalkyl group is the cyclopentenyl group (C5H7-), which is a five carbon (Cs) unsaturated cycloalkyl group.

[00171] “Heterocycle” refers to an optionally substituted 5- to 7-membered cycloalkyl ring system containing 1, 2 or 3 heteroatoms, which can be the same or different, selected from N, O or S, and optionally containing one double bond.

[00172] “Halogen” refers to a chloro, bromo, fluoro or iodo atom radical. The term “halogen” also contemplates terms “halo” or “halide.”

[00173] “Heteroatom” refers to a non-carbon atom, where boron, nitrogen, oxygen, sulfur and phosphorus are preferred heteroatoms, with nitrogen, oxygen and sulfur being particularly preferred heteroatoms in the compounds of the present disclosure.

[00174] “Heteroaryl” refers to optionally substituted aryl groups having from 1 to 9 carbon atoms and the remainder of the atoms are heteroatoms, and includes those heterocyclic systems described in “Handbook of Chemistry and Physics,” 49th edition, 1968, R. C. Weast, editor; The 2026223382   31 Aug 2026 Chemical Rubber Co., Cleveland, Ohio. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems. Suitable heteroaryls include thienyl, pyrrolyl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, pyranyl, tetrazolyl, pyrrolyl, pyrrolinyl, pyridazinyl, triazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl, oxadiazolyl, benzoxazolyl, benzoxadiazolyl, thiadiazolyl, benzothiazolyl, benzothiadiazolyl, and the like.

[00175] An “optionally substituted” moiety can be substituted with from one to four, or preferably from one to three, or more preferably one or two non-hydrogen substituents. Unless otherwise specified, when the substituent is on a carbon, it is selected from the group consisting of -OH, -CN, -NO2, halogen, Ci to C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, none of which are further substituted. Unless otherwise specified, when the substituent is on a nitrogen, it is selected from the group consisting of Ci to C12 alkyl, Ci to C12 heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, sulfonyl, sulfonate and sulfonamide none of which are further substituted.

[00176] The term “sulfonamide” as used herein contemplates a group having the structure O ----g---N RN2 0          wherein RN is selected from the group consisting of hydrogen, -OH, Ci to C12 alkyl, Ci to C12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide.

[00177] The term “sulfonate” as used herein contemplates a group having the structure O ----g---Q RS O         wherein Rs is selected from the group consisting of hydrogen, C1-C10 alkyl, C2- C10 alkenyl, C2-C10 alkynyl, C1-C10 alkanoyl, or C1-C10 alkoxycarbonyl.

[00178] “Sulfonyl” as used herein alone or as part of another group, refers to an SO2 group. The SO2 moiety is optionally substituted. 2026223382   31 Aug 2026

[00179] Compounds of the present disclosure can exist as stereoisomers, wherein asymmetric or chiral centers are present. Stereoisomers are designated (R) or (S) depending on the configuration of substituents around the chiral carbon atom. The terms (R) and (S) used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., (1976), 45: 13-30, hereby incorporated by reference. The present disclosure contemplates various stereoisomers and mixtures thereof and are specifically included within the scope of the present disclosure. Stereoisomers include enantiomers, diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the present disclosure can be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.

[00180] Also, moieties disclosed herein which exist in multiple tautomeric forms include all such forms encompassed by a given tautomeric structure.

[00181] Individual atoms m the disclosed compounds may be any isotope of that element. For example hydrogen may be in the form of deuterium.

[00182] “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans. It can be material which is not biologically or otherwise undesirable, i.e,, the material can be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[00183] The term “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include, for example, acid addition salts and base addition salts.

[00184] “Acid addition salts” according to the present disclosure, are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, 2026223382   31 Aug 2026 cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfomc acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-l-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l -carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like.

[00185] “Base addition salts” according to the present disclosure are formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. It should be understood that a reference to a pharmaceutically acceptable salt includes the solvent addition forms or crystal forms thereof, particularly solvates or polymorphs. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and are often formed during the process of crystallization. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Polymorphs include the different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Various factors such as the recrystallization solvent, rate of crystallization, and storage temperature can cause a single crystal form to dominate.

[00186] The term “treating” includes the administration of the compounds or agents of the present invention to a subject to prevent or delay, to alleviate, or to arrest or inhibit development of the symptoms or conditions associated with fatty acid synthase-associated disorders, e.g., tumor growth associated with cancer. A skilled medical practitioner will know how to use standard methods to determine whether a patient is suffering from a disease associated with activity of fatty acid synthase, e.g., by examining the patient and determining whether the patient is suffering from a disease known to be associated with fatty acid synthase activity or by assaying for fatty acid synthase levels in blood plasma or tissue of the individual suspected of suffering from fatty acid 2026223382   31 Aug 2026 synthase associated disease and comparing fatty acid synthase levels in the blood plasma or tissue of the individual suspected of suffering from a fatty acid synthase associated disease with fatty acid synthase levels in the blood plasma or tissue of a healthy individual. Increased securin levels are indicative of disease. Accordingly, the present invention provides, inter alia, methods of administering a compound of the present invention to a subject and determining fatty acid synthase activity in the subject. Fatty acid synthase activity in the subject can be determined before and / or after administration of the compound.

[00187] A “therapeutically effective amount” or “pharmaceutically effective amount” means the amount that, when administered to a subject, produces effects for which it is administered. For example, a “therapeutically effective amount,” when administered to a subject to inhibit fatty acid synthase activity, is sufficient to inhibit fatty acid synthase activity. A “therapeutically effective amount,” when administered to a subject for treating a disease, is sufficient to effect treatment for that disease.

[00188] Except when noted, the terms “subject” or “patient” are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats, and mice, and other animals. Accordingly, the term “subject” or “patient” as used herein means any mammalian patient or subject to which the compounds of the invention can be administered. In an exemplary aspect of the present invention, to identify subject patients for treatment according to the methods of the invention, accepted screening methods are employed to determine risk factors associated with a targeted or suspected disease or condition or to determine the status of an existing disease or condition in a subject. These screening methods include, for example, conventional work-ups to determine risk factors that are associated with the targeted or suspected disease or condition. These and other routine methods allow the clinician to select patients in need of therapy using the methods and formulations of the present invention. FASN Pathway Modulators

[00189] One aspect of the present disclosure includes a method of inhibiting viral infection or treating cancer by contacting a cell with an agent that modulates the fatty acid synthesis pathway. This method of inhibiting viral infection or treating cancer can be performed in vitro by contacting virally infected / cancerous cells with an agent that modulates the fatty acid synthesis pathway, or in vivo by administering an agent that modulates the fatty acid synthesis pathway to a 2026223382   31 Aug 2026 subject infected with a virus / having cancer. In one aspect, an agent can be an inhibitor of the fatty acid synthesis pathway.

[00190] Examples of inhibitors of the fatty acid synthesis pathway that can be used in the methods and compositions of the present disclosure are described below. Compounds of Structure (I)

[00191] In various aspects, the present disclosure provides for compounds of Structure (I): (B or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is hydrogen or Ci-6 alkyl and R' is hydrogen, Ci-6 alkyl, or absent; A is CH or N; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ct-6 alkoxy, -C(=O)N(Rb)(R14), -(CH2)qC(=O)N(Ri3)(Ri4), CF3, -OCF3, or -S(=O)2R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Ci-6 alkyl, Ci-6 alkoxy, or -N(Ri3)(Ri4); R? is hydrogen, halo, Ci-6 alkoxy, Ci-6 alkyl, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Ra is hydrogen, hydroxyl, halo, Ci-6 alkyl, Ci-6 alkoxy, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5Re), -N(R.7)C(=::O)Rs, -N(R9Rio), Ci-6 alkyl, Ci-e alkoxy, -S(:=0)2R2o, or R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; R11 is hydrogen, halo, cyano, C1-6 alkyl, Ci-6 alkoxy, -N(Ri3Ri4), CF3, -OCF3, -S(=:0)2R2o, Ra and R11 taken together with the atoms to which they are attached join together to form a heteroaryl, or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; 2026223382   31 Aug 2026 R12 is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(Ri3Ri4), CF3, -OCF3, -S(=:0)2R2o,or R11 and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Re, Rt, Rs, R9 Rio, R13, and R14 are each independently hydrogen, Ct-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R15Rj6), or -S(=0)2R2o; R15 and Rie are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino; R17 and Ris are each independently hydrogen or alkyl or can optionally join together to form a bond; n is 1 or 2; and m is 0 or 1.

[00192] In certain aspects of Structure (I), Ra is F.

[00193] In certain aspects of Structure (I), A is CH.

[00194] In certain aspects of Structure (I), A is N.

[00195] In certain aspects of Structure (I), X, Y, and Z are NR'.

[00196] In certain aspects of Structure (I), R4 is heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R7)C(=O)Rs, -N(R9Rio), Ci-e alkyl, C1-6 alkoxy, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl.

[00197] In certain aspects of Structure (I), Rs is hydrogen and Re is aryl or heteroaryl.

[00198] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-A) or (I-B): (I-A)                                        (I-B) or a pharmaceutically acceptable salt thereof) wherein: X, Y, and Z are each independently CR or NR', wherein R is hydrogen or C1-6 alkyl and R' is hydrogen, Ci-s alkyl, or absent; Ri is hydrogen, cyano, halo, C1-6 alkyl, C1-6 alkoxy, -C(=O)N(R13)(R14), ~(CH2)qC(=O)N(Ri3)(Ri4), CF3, -OCF3, or -S(=0)2R2o; 2026223382   31 Aug 2026 q is 0, 1, 2, 3, or 4; Rao is hydrogen or Ci-6 alkyl, Ci-6 alkoxy, or -N(Ri3)(Ri4); R2 is hydrogen, halo, C1-6 alkoxy, C1-6 alkyl, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rs is hydrogen, hydroxyl, halo, Ci-6 alkyl, Cj-s alkoxy, or Ra and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R7)C(=O)Rs, -N(R9Rio), Cn 6 alkyl, Ci-e alkoxy, -S(=O)2R20, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; R11 is hydrogen, halo, cyano, Cns alkyl, Ci-s alkoxy, -N(R13R14), CF3, -OCF3, -S(=O)2R20, R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl, or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, Ci-s alkyl, C1-6 alkoxy, -N(R13R14), CF3, -OCF3, -S(=O)2R20,or R11 and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R5, Rs, R7, Rs, R9 Rio, R13, and R14 are each independently hydrogen, Ci-s alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R15Ris), or -S(==0)2R20; R15 and Ris are each independently hydrogen, Ci-s alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino; and R17 and Ris are each independently hydrogen or alkyl or can optionally join together to form a bond.

[00199] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-C) or (I-D): or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is hydrogen or C1-6 alkyl and R' is hydrogen, C1-6 alkyl, or absent;; 2026223382   31 Aug 2026 R2 is hydrogen, halo, Ci-6 alkoxy, Ci-6 alkyl, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R? is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or R2 and R? taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(RsR6), -N(R7)C(=O)R«, -N(R9Rio), Cn 6 alkyl, Ci-6 alkoxy, -S(=O)2R20, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; R20 is hydrogen or Cj-6 alkyl, C1-6 alkoxy, or -N(Rh)(R]4); Rii is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(RbRi4), CFs, -OCF3, -S(=O)2R20, or Ri and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Re, R7, Rs, Rs, and Rio are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and R15 and Rte are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00200] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-E), (I-F), (I-G), (I-H): (I-E)                                           (I-F) (I-G)                                        (I-H) or a pharmaceutically acceptable salt thereof, wherein: R2 is hydrogen, halo, C1-6 alkoxy, C1-6 alkyl, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; 2026223382   31 Aug 2026 R3 is hydrogen, hydroxyl, halo, Ci-6 alkyl, Ci-6 alkoxy, or R?. and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(:=O)R8, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, ~S(=O)2R20, or Ri and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; R20 is hydrogen or Cj-6 alkyl, Ci-6 alkoxy, or -N(Rh)(R]4); Rii is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(RbRi4), CFs, -OCF3, -S(=O)2R20, R4 and Ri 1 taken together with the atoms to which they are attached join together to form a heteroaryl, or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, C1-6 alkyl, Ct-6 alkoxy, -N(Rt3Ri4), CF3, -OCF3, -S(=0)2R2o,or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Re, R7, Rs, Rs, Rio, R13, and R14 are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisRi6); and R15 and Rte are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00201] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-I), (I-J), or (I-K): (I-K) or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 X and Y are each independently CR or NR', wherein R is H or Ci-6 alkyl and R' is H, Ci-6 alkyl, or absent; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, -C(=O)N(Ri3)(Ri4), (O HqG: O)N(Rr.)(Ru). CF3, OCR. or S( ()) 20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cj-6 alkyl, C1-6 alkoxy, or -N(Rh)(R14); R2 is hydrogen, halo, Ci-6 alkoxy, Ct-6 alkyl, or Ra and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; is hydrogen, hydroxyl, halo, Ci-6 alkyl, Cj-6 alkoxy, or Ra and Rj taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rii is hydrogen, halo, cyano, C1-6 alkyl, Ct-6 alkoxy, -N(Rt3Ri4), CF3, -OCF3, or -~S(=0)aR2o; R5, Rs, R?, Rs, R9, and Rio are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and R15 and Ris are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00202] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-L) or (I-M): or a pharmaceutically acceptable salt thereof, wherein: X and Y are each independently CR or NR', wherein R is H or C1-6 alkyl and R' is H, C1-6 alkyl, or absent; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R7)C(=O)Rs, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, -S(=0)2Rao, or R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; 2026223382   31 Aug 2026 R20 is hydrogen or Ci-6 alkyl, Ci-6 alkoxy, or -N(Ri3)(Ri4); Rn is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, ~N(Ri3Ri4), CF3, --OCF3, -S(=O)2R20, or R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Ro, R7, Rs, R9, and Rio are each independently H, Cno alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -NfRisRie); and Ris and Rio are each independently H, Cno alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00203] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-N) or (I-O): (I-N) HN N , or N (I-O) or a pharmaceutically acceptable salt thereof.

[00204] In certain aspects, the compounds of Structure (I) have the following Structure (I 2026223382   31 Aug 2026 (i-p) or a pharmaceutically acceptable salt thereof; wherein: R? is hydrogen, halo, Ci-o alkoxy, Ci-6 alkyl, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rs is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or Ra and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R7)C(=O)Rs, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, -S(=O)2R20, or R4 and Ru taken together with the atoms to which they are attached join together to form a heteroaryl; Rao is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(Ris)(R14); R11 is hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, -N(R13R14), CF3, -OCF3, -S(=0)aR2o, R4 and Ru taken together with the atoms to which they are attached join together to form a heteroaryl, or Ru and Ria taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, Cno alkyl, C1-6 alkoxy, -N(RbR14), CFs, -OCF3, -S(=O)2R20,or Ru and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Ro, R?, Rs, R9, Rio, Rj3, and Ru are each independently H, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and R15 and Rio are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00205] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-Q), (I-R), or (I-S): 2026223382   31 Aug 2026 (l-Q) (LR) (I-S) or a pharmaceutically acceptable salt thereof,

[00206] In certain aspects, the compounds of Structure (I) have the following Structure (I T): (LT) or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is H or Ci-6 alkyl and R' is H, Ci-6 alkyl, or absent; 2026223382   31 Aug 2026 Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, ”C(=O)N(Ri3)(Ri4), ---(CHi)qC( O)X(Ri3)(Ru). CF3, ()(T'3, or S(O) R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cj-6 alkyl, C1-6 alkoxy, or ~-N(Ri3)(R]4); R2 is hydrogen, halo, Ci-6 alkoxy, Ci-6 alkyl, or R? and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Ri is hydrogen, hydroxyl, halo, Ci-6 alkyl, Cj-e alkoxy, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(RsR6), -N(R7)C(=0)R«, -N(R9Rio), Cn 6 alkyl, Ci-6 alkoxy, -S(=O)2R20, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; Rn is hydrogen, halo, cyano, Ci-e alkyl, C1-6 alkoxy, -N(R13R14), CF3, -OCF3, -S(=O)2R20, R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl, or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, Ci-e alkyl, C1-6 alkoxy, -N(R13R14), CF3, -OCF3, -S(=O)2R20,or R11 and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Re, R7, Rs, R9, Rio, R13, and R14 are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and Ris and Rie are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00207] In certain aspects, the compounds of Structure (I) have the following Structure (I-U): H (I-U) 2026223382   31 Aug 2026 or a pharmaceutically acceptable salt thereof.

[00208] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-V): (LV) or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is H or Ci-6 alkyl and R' is H, Ci-6 alkyl, or absent; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ct-6 alkoxy, -C(=O)N(Rb)(R14), -(CII2)qC(==O)N(R13)(R14), CF3, -OCF3, or -S(=0)2R2o; q is 0, 1, 2, 3, or 4; R2o is hydrogen or Ci-s alkyl, Ci-6 alkoxy, or -N(R13)(Rm); R2 is hydrogen, halo, Ci-6 alkoxy, Ci-6 alkyl, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5Re), -N(R?)C(=:O)R8, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, -S(:=0)2R2o, or R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; R11 is hydrogen, halo, cyano, C1-6 alkyl, Ci-6 alkoxy, -N(Ri3Rm), CF3, -OCF3, -S(=0)2R2o, R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl, or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, C1-6 alkyl, Ci-6 alkoxy, -N(Ri3Ri4), CF3, -OCF3, -S(=O)2R20,or R11 and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Re, R?, Rs, R9, Rio, R13, and Rm are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and 2026223382   31 Aug 2026 Ris and Ri6 are each independently H, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00209] In certain aspects, the compound of Structure (I) has the following Structure (I-W): (I-W) or a pharmaceutically acceptable salt thereof.

[00210] In certain aspects, the compounds of Structure (I) have one of the following Structures (I-X), (I-Y), (I-Z), (I-AA), (I-AB), (I-AC), (I-AD), (I-AF), (I-AG), or (I-AH): 2026223382   31 Aug 2026 2026223382   31 Aug 2026 (I-AH) or a pharmaceutically acceptable salt thereof. Compounds of Structure (II)

[00211] In various aspects, the present disclosure provides for compounds of Structure (II): 2026223382   31 Aug 2026 (ii) or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is H or Ci-6 alkyl and R' is H, Ci-6 alkyl, or absent; L and D are each independently C or N; Ri is hydrogen, cyano, halo, Cj-6 alkyl, Ci-6 alkoxy, -C(=O)N(Rj3)(R14), -(CH2)qC(=O)N(Rn)(Rf 4), CFs, -OCF3, or-S(=0)2R2o; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Ct-6 alkyl, C1-6 alkoxy, or -N(R13)(Rm); Rz is hydrogen, halo, C1-6 alkoxy, Cj-6 alkyl, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rs is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or R2 and R3 taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(=O)R8, -N(R$Rio), Ci-6 alkyl, Ci-6 alkoxy, -S(=O)2R20, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; Rii is hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, -N(R13Rm), CF3, -OCF3, -S(=0)2R2o, R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl, or R11 and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, -N(R13R14), CF3, -OCF3, -S(=O)2R20,or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, R&, R7, Rs, R9, Rio, R13, and R14 are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); R15 and Rio are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino; R17 and Ris are each independently hydrogen or alkyl or can optionally join together to form a bond; n is 1 or 2; and m is 0 or 1. 2026223382   31 Aug 2026

[00212] In certain aspects, the compounds of Structure (II) have the following Structure (II-A): (n-A) or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is H or Cue alkyl and R' is H, Cue alkyl, or absent; R> is hydrogen, halo, Cue alkoxy, Cue alkyl, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rs is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(=O)R8, -N(R$Rio), Ci-6 alkyl, Ci-6 alkoxy, -S(=O)2R20, or R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(Ris)(R14); R11 is hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, -N(RisR14), CFs, -OCF3, -S(=O)2R20, R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl, or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; R12 is hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, -N(RisR14), CFs, -OCF3, -S(=O)2R20,or Rn and R12 taken together with the atoms to which they are attached join together to form a heteroaryl; Rs, Re, R7, Rs, R9, Rio, R13, and Rm are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and Ris and Rie are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino. 2026223382   31 Aug 2026

[00213] In certain aspects, the compounds of Structure (II) have the following Structure (II-B): (ll-B) or a pharmaceutically acceptable salt thereof, wherein: X and Y are each independently CR or NR', wherein R is H or Cns alkyl and R' is H, Ci-6 alkyl, or absent; Rz is hydrogen, halo, Ci-6 alkoxy, Cj-6 alkyl, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rs is hydrogen, hydroxyl, halo, C1-6 alkyl, C1-6 alkoxy, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(=O)R8, -N(RsRio), Ci-6 alkyl, Ci-6 alkoxy, -S(=O)2R20, or R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(Ris)(R14); R11 is hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, -N(RisR14), CFs, -OCFs, -8(-0)21^20, or R4 and R11 taken together with the atoms to which they are attached join together to form a heteroaryl; Ro, Re, R7, Rs, R9, and Rio are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and R15 and Rie are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00214] In certain aspects, the compounds of Structure (II) have one of the following Structures (II-C), (H-D), or (II-E): 2026223382   31 Aug 2026 (II-E) or a pharmaceutically acceptable salt thereof; wherein: X and Y are each independently CR or NR', wherein R is H or Ci-6 alkyl and R' is H, Ci-6 alkyl, or absent; R? is hydrogen, halo, Ci-6 alkoxy, Ci-6 alkyl, or R2 and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rs is hydrogen, hydroxyl, halo, Ci-6 alkyl, Ci-6 alkoxy, or Rs and Rs taken together with the atoms to which they are attached form a 5-membered heterocyclyl; Rn is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(RisR14), CF3, -OCFs,or S( O)2i<w Rao is hydrogen or C1-6 alkyl, C1-6 alkoxy, or --N(Ri3)(Rm); Rs, R&, R7, Rs, R% and Rio are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisR16); and Ris and Rio are each independently H, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00215] In certain aspects, the compound of Structure (II) has the following Structure (II-F): 2026223382   31 Aug 2026 (n-F) or a pharmaceutically acceptable salt thereof. Compounds of Structure (III)

[00216] In various aspects, the present disclosure provides for compounds of Structure (III): (III) or a pharmaceutically acceptable salt thereof, wherein: X, Y, and Z are each independently CR or NR', wherein R is H or Ci-6 alkyl and R' is H, Ci-6 alkyl, or absent; Q is C or N; Rj is hydrogen, hydroxyl, halo, Ci-6 alkyl, Ci-6 alkoxy, or if Q is N Rs is absent; Rr is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5R6), -N(R?)C(:=O)R8, -N(R9Rio), Ci-6 alkyl, Ci-6 alkoxy, -S^O^Rzo, or R4 and Ru taken together with the atoms to which they are attached join together to form a heteroaryl; R20 is hydrogen or Ci-6 alkyl, Ci-6 alkoxy, or --N(Ri3)(Rm); R11 is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(Ri3Ri4), CF3, -OCF3, -S^OjzRzo, R4 and Ru taken together with the atoms to which they are attached join together to form a heteroaryl, or Ru and R12 taken together with the atoms to winch they are attached join together to form a heteroaryl; Riz is hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, -N(RbR14), CF3, -OCF3, -S(=O)2R20,or Ru and Rn taken together with the atoms to which they are attached join together to form a heteroaryl;; 2026223382   31 Aug 2026 Rs, R&, R7, Rs, R9, Rio, R13, and R14 are each independently H, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisRi6); Ris and Rio are each independently H, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino; R17 and Ris are each independently hydrogen or alkyl or can optionally join together to form a bond; R19 is aryl, heteroaryl, cycloalkyl, or heterocyclyl; n is 0, 1, or 2; and m is 0 or 1.

[00217] In certain aspects, the compounds of Structure (III) have one of the following Structures (III-A), (III-B), or (III-C): (III-C) or a pharmaceutically acceptable salt thereof, wherein: X and Y are each independently CR or NR', wherein R is H or Cue alkyl and R' is H, Ci-6 alkyl, or absent; Rs is hydrogen, hydroxyl, halo, Cue alkyl, or Cue alkoxy; R4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R5Re), -N(R?)C(=O)Rb, -N(R9Rio), Cn e alkyl, Cue alkoxy, -S(=O)2R20, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; Rr. is hydrogen, halo, cyano, Cue alkyl, C1-6 alkoxy, -N(R13R14), CFs, -OCF3, -S(=O)2R20, or R4 and Rn taken together with the atoms to which they are attached join together to form a heteroaryl; 2026223382   31 Aug 2026 Rs, R&, R7, Rs, Ry and Rio are each independently H, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(RisRi6); and Ris and Rio are each independently H, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylamino.

[00218] In certain aspects, the compounds of Structure (III) have one of the following Structures (III-D), (III-E), or (IH-F): (III-D) (III-E)                                            (Hl-1 ) or a pharmaceutically acceptable salt thereof. Compounds of Structure (IV)

[00219] In certain aspects, the compounds of Structure (IV) have one of the following Structures (IV-A), (IV-B), or (IV-C): ^26 (IV-A)                                 (IV-B) 2026223382   31 Aug 2026 R2S (IV-C) or a pharmaceutically acceptable salt thereof, wherein: Li, L2, L3, L4, and A are each independently CH or N; Ri is hydrogen, cyano, halo, Ci-s alkyl, Ci-6 alkoxy, -C(=O)N(R13)(R14), -(CH2)qC(=O)N(Ri3)(Ri4), CF3, “OCF3, or-S(=0)2R2o; q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(R13)(R14); R2 is hydrogen, halo. C1-6 alkoxy, or Ci-6 alkvl; Ra is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Ci-s alkoxy, CF3, -OCR or S( Oi’R.x R23 is hydrogen, -N(R13)(R14), C1-6 alkyl, C1-6 alkoxy, is absent if Li is N, or R23 and R24 taken together with the atoms to which they are attached join together to form a heterocyclyl, heteroaryl, or cycloalkyl; R24 is hydrogen, -N(R13)(R14), C1-6 alkyl, C1-6 alkoxy, -(C1-6 alkoxy)(heterocyclyl), heterocyclyl, or R23 and R24 taken together with the atoms to which they are attached join together to form a heterocyclyl, heteroaryl, or cycloalkyl; R2.6 is hydrogen, heteroaryl, heterocyclyl, ~-N(Ri3)(Ri4), or S{ ())^R R13 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -NfRisRie), or ~S(=0)2R2o; R25 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; and R15 and Ri6 are each independently hydrogen, C1-6 alkyl, C1-6 alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[00220] In certain aspects, the compounds of Structure (IV) have one of the following Structures (IV-D) and (IV-E): 2026223382   31 Aug 2026 (IV-D)                                 (IV-E) or a pharmaceutically acceptable salt thereof. Ri is hydrogen, cyano, halo, Ct-6 alkyl, Ct-6 alkoxy, -C(=O)N(Rb)(R14), -(CH2)qC(=O)N(Ri3)(Ri4), CF3, OCR. or S(=0)2R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cj-6 alkyl, C1-6 alkoxy, or -N(Ris)(R14); R2 is hydrogen, halo, Ci-6 alkoxy, or Cj-6 alkyl; Rs is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, Cue alkyl, Ci-6 alkoxy, CFs, -OCF3, or S(O) R20; R26 is hydrogen, heteroaryl, heterocyclyl, -N(R13)(Rm), or ~S(=0)2R2o; Ri3 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(RisR16), or -S(=0)2R2o; R25 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; and R15 and Rie are each independently hydrogen, Cue alkyl, C1-6 alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[00221] In certain aspects, the compounds of Structure (IV) have one of the following Structures (IV-F) and (TV-G): (IV-F)                                   (IV-G) or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, ”C(=O)N(Ri3)(Ri4), (O HqC( O‘X(Rh)(Ru). CF3, --OCF3, or S( 0) R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cj-6 alkyl, C1-6 alkoxy, or -N(R13)(R]4); R2 is hydrogen, halo, Ci-6 alkoxy, or Cj-6 alkyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, Cue alkyl, Ct-6 alkoxy, CF3, -OCF3, or -S(=0)2R2o; R13 and Ru are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(Ri5Ri6), or -S(=0)2R2o; R25 is hydrogen, C1-6 alkyl, or Ci-6 alkoxy; Ri5 and Ri6 are each independently hydrogen, C1-6 alkyl, Ci-s alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; s is 0, 1, or 2; L5 is CH2, NH, S, or O; Ls is CH or N; Ra? is hydrogen, -C(=O)R", -S(=0)2R2o; R28 is hydrogen, -C(=O)R”, “S(=0)2R2o, or is absent if Le is O; and R" is hydrogen, C1-6 alkyl, C1-6 alkoxy, -C(=O)N(R13)(R14), or -N(R13)(R14).

[00222] In certain aspects of Structure (IV), Ri is hydrogen, cyano, C1-6 alkyl, C1-6 alkoxy, or -C(:=O)N(Ri3)(Ri4).

[00223] In certain aspects of Structure (IV), Ri is cyano.

[00224] In certain aspects of Structure (IV), R2 is hydrogen or halo; R2 is hydrogen.

[00225] In certain aspects of Structure (IV), R3 is hy drogen.

[00226] In certain aspects of Structure (IV), R21 and R22 are each independently hydrogen or Ci-6 alkyl.

[00227] In certain aspects of Structure (IV), R21 and R22 are each independently Ci-6 alkyl.

[00228] In certain aspects of Structure (IV), Rzs is hy drogen.

[00229] In certain aspects of Structure (IV), L2 is N.

[00230] In certain aspects of Structure (IV), Li is CH.

[00231] In certain aspects of Structure (IV), L3 is CH. 2026223382   31 Aug 2026

[00232] In certain aspects of Structure (IV), L4 is CH.

[00233] In certain aspects of Structure (IV), A is N.

[00234] In certain aspects of Structure (IV), A is CH.

[00235] In certain aspects of Structure (IV), R26 is heterocyclyl.

[00236] In certain aspects of Structure (IV), R24 is -N(Rh)(R14).

[00237] In certain aspects of Structure (IV), Ls and Le are each independently N. In certain aspects of Structure (IV), s is 1.

[00238] In certain aspects of Structure (IV), s is 0.

[00239] In certain aspects, the compounds of Structure (IV) have one of the following Structures (IV-H), (IV-I), (IV-J), (IV-K), (IV-L), (IV-M), (IV-N), or (IV-O): q            0                °x y~N >—u      K               '—h N ''Af      N                    N H || J f 1                               H (IV-H) 0 x—C u     J n H (IV-J) <kNQx 1 (IV-K) O (IV-I) 7 2026223382   31 Aug 2026 (IV-O) or a pharmaceutically acceptable salt thereof. Compounds of Structure (V)

[00240] In various aspects, the present disclosure provides for compounds of Structure (V): 2026223382   31 Aug 2026 (V) or a pharmaceutically acceptable salt thereof! wherein: L7 is N or O, wherein Rao is absent if L7 is O; A is CH or N; Ri is hydrogen, cyano, halo, C1-6 alkyl, Ct-6 alkoxy, -C(=O)N(Rb)(R14), ~(CH2)qC(=O)N(Ri3)(Ri4), CF3, -OCF3, or -S(=O)2R20; q is 0, 1, 2, 3, or 4; R2o is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(Ri3)(R14); R? is hydrogen, halo, C1-6 alkoxy, or C1-6 alkyl; R3 is halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, C1-6 alkoxy, CF3, ---OCF3, or S{ 0)   : R29 and Rao are each independently hydrogen, C1-6 alkyl, C1-6 alkoxy, hydroxyalkyl, heteroaryl, heterocyclyl, -N(Ri5Ri6), -C(;=O)R46, -R4sC(:=O)R47, or R29 and R30 taken together with the atoms to which they are attached join together to form a heteroaryl or heterocyclyl, wherein R30 is absent if L7 is O; R46 and R47 are each independently hydrogen, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, -N(Ri5Ri6), or ”S(=0)2R2o; R48 is alkyl or is absent; R31 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; R13 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(RjsRj6), or -S(=0)2R2o; R15 and Rie are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; and v is 0 or 1. 2026223382   31 Aug 2026

[00241] In certain aspects, the compounds of Structure (V) have one of the following Structures (V-A), (V-B), (V-C), or (V-D): (V-C)                                 (V-D) or a pharmaceutically acceptable salt thereof, wherein: Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, -C(=O)N(Ri3)(Ri4), -(CH2)qC(=O)N(Rn)(Ri4), CFs, -OCF3, or-S(=0)2R2o; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Ci-6 alkyl, C1-6 alkoxy, or -N(R13)(Rm); R> is hydrogen, halo, C1-6 alkoxy, or Ct-6 alkyl; R3 is halo, Ci-6 alkyl, or Ci-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Ci-6 alkoxy, CFy --OCF3, or S( O) ’R .< R30 is hydrogen, C1-6 alkyl, C1-6 alkoxy, hydroxyalkyl, heteroaryl, heterocyclyl, -N(R15R16), “C(=O)R46, or ~R4sC(=O)R47, wherein R30 is absent if I" is O; R46 and R47 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, -N(Ri5Rie), or -S(=0)2R2o; 2026223382   31 Aug 2026 R48 is alkyl or is absent; R31 is hydrogen, Ci-6 alkyl, or Ci-6 alkoxy; Rw and R14 are each independently hydrogen, Ci-e alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, ~N(Rt5Ri6), or -S(=0)2R2o; Ris and Ri6 are each independently hydrogen, Cue alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; Lg, L9, and Lio are each independently CH2, NH, or O; Lu and Lu are each independently CH or N; R32 and Ru are each independently hydrogen, Cue alkyl, Ct-6 alkoxy, -S(=O)2R20, -C(=O)R46, hydroxyalkyl, hydroxyl, or are absent; u is 0, 1, or 2; and t is 0, 1, or 2.

[00242] In certain aspects of Structure (V), 1.,7 is N.

[00243] In certain aspects of Structure (V), L7 is O.

[00244] In certain aspects of Structure (V), A is N.

[00245] In certain aspects of Structure (V), A is CH.

[00246] In certain aspects of Structure (V), Ri is hydrogen, cyano, C1-6 alkyl, C1-6 alkoxy, or ”C(=0)N(Ru)(R14).

[00247] In certain aspects of Structure (V), Ri is cyano.

[00248] In certain aspects of Structure (V), R2 is hydrogen or halo.

[00249] In certain aspects of Structure (V), R2 is hydrogen.

[00250] In certain aspects of Structure (V), R3 is fluorine.

[00251] In certain aspects of Structure (V), R21 and R22 are each independently hydrogen or Ci-6 alkyl.

[00252] In certain aspects of Structure (V), R21 and R22 are each independently Ci-6 alkyl.

[00253] In certain aspects of Structure (V), R31 is hy drogen.

[00254] In certain aspects of Structure (V), R30 is hydrogen.

[00255] In certain aspects of Structure (V), Ls is O.

[00256] In certain aspects of Structure (V), L9 is 0.

[00257] In certain aspects of Structure (V), Lio is O and Ln is N.

[00258] In certain aspects of Structure (V), L12 is N. 2026223382   31 Aug 2026

[00259] In certain aspects of Structure (V), R32 and R33 are each independently hydrogen.

[00260] In certain aspects, the compounds of Structure (V) have one of the following 2026223382   31 Aug 2026 (V-O) or a pharmaceutically acceptable salt thereof. Compounds of Structure (VI)

[00261] In certain aspects, the compounds of Structure (VI) have one of the following Structures (VI-A) or (VI-B): or a pharmaceutically acceptable salt thereof, wherein: Lb, Li4, Lis, and A are each independently CH or N; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, “C(=O)N(Rb)(R14), ((MC( (WHOM CF3, -OCF3, or S( O)'R'< q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or -N(Ri3)(Ri4); R2 is hydrogen, halo, C1-6 alkoxy, or C1-6 alkyl; R3 is halo, Ci-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Cj-6 alkoxy, CF3, - OCF3, or S{ 0) ‘R R34 is hydrogen, Ci-6 alkyl, C1-6 alkoxy, cycloalkyl, hydroxyl, hydroxyalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, CF3, -OCF3, -S(=O)2R20, or -N(R15R16); R35 is hydrogen, Ci-6 alkyl, or Ci-6 alkoxy; 2026223382   31 Aug 2026 R36 is hydrogen, Ci-6 alkyl, Ci-6 alkoxy, -N(Ri5Rie), heterocyclyl, or heteroaryl; R13 and R14 are each independently hydrogen, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -NfRisRie), or ~S(=0)2R2o; and Ris and Rie are each independently hydrogen, Ci-6 alkyl, Ci-6 alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[00262] In certain aspects, the compounds of Structure (VI) have one of the following Structures (VI-C) or (VI-D): (VI-C)              or                  (VI-D) or a pharmaceutically acceptable salt thereof, wherein: Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ct-6 alkoxy, -C(=O)N(R13)(R14), -(CII2)qC(==O)N(R13)(R14), CF3, -OCF3, or -S(=O)2R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Ci-s alkyl, Ci-6 alkoxy, or -N(R13)(R14); Rj is hydrogen, halo, C1-6 alkoxy, or Ci-s alkyl; Rs is halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, Ci-6 alkyl, C1-6 alkoxy, CF3, -OCF3, or S( ()HC< R35 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; R36 is hydrogen, Ci-e alkyl, C1-6 alkoxy, -N(Ri5Rie), heterocyclyl, or heteroaryl; Ri3 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R15R16), or -S(=0)2R2o; Ris and Rie are each independently hydrogen, Cue alkyl, C1-6 alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; and 2026223382   31 Aug 2026 R37 and R38 are each independently hydrogen, Ci-6 alkyl, Ci-6 alkoxy, hydroxyalkyl, heteroaryl, heterocyclyl, or R37 and R38 taken together with the atoms to which they are attached join together to form a heteroaryl or heterocyclyl.

[00263] In certain aspects of Structure (VI), Rj is hydrogen, cyano, Cj-6 alkyl, Cue alkoxy, or -C(=O)N(Rj3)(R14).

[00264] In certain aspects of Structure (VI), Ri is cyano.

[00265] In certain aspects of Structure (VI), Rz is hydrogen or halo.

[00266] In certain aspects of Structure (VI), R2 is hydrogen.

[00267] In certain aspects of Structure (VI), R3 is fluorine.

[00268] In certain aspects of Structure (VI), R?.j and R22 are each independently hydrogen or C1-6 alkyl.

[00269] In certain aspects of Structure (VI), R21 and R22 are each independently C1-6 alkyl.

[00270] In certain aspects of Structure (VI), R35 is hydrogen.

[00271] In certain aspects of Structure (VI), R34 is heteroaryl;

[00272] In certain aspects of Structure (VI), R34 is thienyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, pyranyl, tetrazolyl, pyrrolyl, pyrrolinyl, pyridazinyl, triazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl, oxadiazolyl, benzoxazolyl, benzoxadiazolyl, thiadiazolyl, benzothiazolyl, or benzothiadiazolyl.

[00273] In certain aspects of Structure (VI), L13 is N.

[00274] In certain aspects of Structure (VI), L14 and Lis are each independently CH.

[00275] In certain aspects of Structure (VI), A is N.

[00276] In certain aspects of Structure (VI), A is CH. 2026223382   31 Aug 2026

[00277] In certain aspects, the compounds of Structure (VI) have one of the following Structures (VI-E), (VI-F), (VI-G), (VI-H), or (VI-I): 2026223382   31 Aug 2026 (VI-H) (VI-I) or a pharmaceutically acceptable salt thereof.

[00278] In various aspects, the present disclosure provides for compounds of Structure (VM): or a pharmaceutically acceptable salt thereof! wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2! is cyclobutyl, azetidin-l-yl, or cyclopropyl; R22 is H, halogen, or C1-C2 alkyl; R35 is -C(O)-R351, -C(O)-NHR351, -C(O)-O-R351 or S(O)2R351; and R’31 is C1-C6 straight or branched alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted.

[00279] In some aspects of Structure (VI-J), R3 is H or halogen.

[00280] In some aspects of Structure (VI-J), R'1 is halogen, -CN or C1-C2 haloalkyl.

[00281] In some aspects of Structure (VI-J), R22 is C1-C2 alkyl. 2026223382   31 Aug 2026

[00282] In some aspects of Structure (VI-J), R21 is cyclobutyl and R22 is C1-C2 alkyl.

[00283] In some aspects of Structure (VI-J), R21 is cyclobutyl.

[00284] In some aspects of Structure (VI-J), R3 is H or F.

[00285] In some aspects of Structure (VI-J), R1 is -CN.

[00286] In some aspects of Structure (VI-J), R! is -CFs.

[00287] In some aspects of Structure (VI-J), R22 is H, methyl or ethyl.

[00288] In some aspects of Structure (VI-J), R22 is H.

[00289] In some aspects of Structure (VI-J), R22 is methyl.

[00290] In some aspects of Structure (VI-J), R33 is -C(O)-NHR351.

[00291] In some aspects of Structure (VI-J), R351 is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)- tetrahydro-2 / f-pyran-3-yl or (S)-tetrahydro-2H-pyran-3-yl.

[00292] In some aspects of Structure (VI-J), R351 is (R)-(tetrahydrofuran-2-yl)methyl or (S)-(tetrahydrofuran-2-yl)methyl.

[00293] In some aspects of Structure (VI-J), R1 is -CN, each R2 is H, R3 is H or F, R21 is C3-C4 cycloalkyl, R22 is H, R33 is -C(O)-NHR351 where R331 is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahydro-2W-pyran-3-yl, or (S)-tetrahydro-2H-pyran-3-yl.

[00294] In some aspects of Structure (VI-J), R35 is -C(O)-O- R351.

[00295] In some aspects of Structure (VI-J), R331 is isopropyl, isobutyl, (R)-3- tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)- tetrahydro-2H-pyran-3-yl, or (S)-tetrahydro-27 / -pyran-3-yl.

[00296] In some aspects of Structure (VI-J), R1 is -CN, each R2 is H, R3 is II or F, R21 is C3-C4 cycloalkyl, R22 is H, R35 is -C(O)-O-R351 where R531 is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)- tetrahydro-2 / / -pyran-3-yl, or (S)-tetrahydro-2H-pyran-3-yl.

[00297] In some aspects of Structure (VI-J), R351 is (R)-3-tetrahydrofuranyl or (S)-3-tetrahy dr ofuranyl. 2026223382   31 Aug 2026

[00298] In some aspects of Structure (VI-J), compounds have a structure selected from the group consisting of: 2026223382   31 Aug 2026 Compounds of Structure (VII)

[00299] In certain aspects, the compounds of Structure (VII) have one of the following Structures (VILA) or (VILB): (VILA)                                    (VILB) or a pharmaceutically acceptable salt thereof, wherein: Lie is C or N, wherein R41 is absent if Lie is N; Li?, Lis, and A are each independently CH or N; Ri is hydrogen, cyano, halo, C1-6 alkyl, Ci-e alkoxy, -C(:=O)N(Ri3)(Ri4), -(CHOlX'iRi3)(Ru). CFu OCH. or S( 0) R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cue alkyl, Cue alkoxy, or -N(R13)(R14); R2 is hydrogen, halo, Ci-6 alkoxy, or Ci-e alkyl; R3 is hydrogen, hydroxyl, halo, Cue alkyl, or Cue alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, Cue alkyl, Ct-6 alkoxy, CF3, -OCF3, or -S(=0)2R2o; R40, R42, and R43 are each independently hydrogen, Cue alkyl, Cue alkoxy, -S(=O)2R20, -C(=O)R, hydroxyalkyl, hydroxyl, -N(R13R14), or R41 and R42 taken together with the atoms to which they are attached join together to form a heteroaryl or heterocyclyl; R41 is hydrogen, C1-6 alkyl, C1-6 alkoxy, -S(=O)2R20, -C(=O)R, hydroxyalkyl, hydroxyl, -N(Ri3Ri4), R41 is absent if Lie is N, or R41 and R42 taken together with the atoms to which they are attached join together to form a heteroaryl or heterocyclyl; R is hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, -N(RisR16), or -S(=0)2R2o; R39 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; 2026223382   31 Aug 2026 Rw and R14 are each independently hydrogen, Ci-e alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, ~N(Ri5Ri6), or --S(=<))a.Rao; and Ris and Ri6 are each independently hydrogen, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[00300] In certain aspects of Structure (VII), Ri is hydrogen, cyano, Cj-6 alkyl, Ci-6 alkoxy, or -C(=O)N(Rt3)(Ri4).

[00301] In certain aspects of Structure (VII), Rj is cyano.

[00302] In certain aspects of Structure (VII), Ra is hydrogen or halo.

[00303] In certain aspects of Structure (VII), Ra is hydrogen.

[00304] In certain aspects of Structure (VII), Ra is hydrogen.

[00305] In certain aspects of Structure (VII), Rai and Raa are each independently hydrogen or Ci-6 alkyl.

[00306] In certain aspects of Structure (VII), R21 and Raa are each independently C1-6 alkyl.

[00307] In certain aspects of Structure (VII), Rn is hydrogen.

[00308] In certain aspects of Structure (VII), R40 is hydrogen.

[00309] In certain aspects of Structure (VII), Lie is N.

[00310] In certain aspects of Structure (VII), Ln is N.

[00311] In certain aspects of Structure (VH). Lis is CH.

[00312] In certain aspects of Structure (VII), Lis is N,

[00313] In certain aspects of Structure (VII), A is N.

[00314] In certain aspects of Structure (VII), A is CH.

[00315] In certain aspects of Structure (All), R4a is C1-6 alkyl.

[00316] In certain aspects of Structure (VII), R41 is Cue alkyl. 2026223382   31 Aug 2026

[00317] In certain aspects, the compounds of Structure (VII) have one of the following Structures (VII-C) or (VII -D): (VII-C)                                         (VII-D) or a pharmaceutically acceptable salt thereof. Compounds of Structure (VIII)

[00318] In certain aspects, the compounds of Structure (VIII) have one of the following Structures (VIII-A), (VJU-B), or (VIII-C): (VIII-A)                                          (VIII-B) (vin-c) or a pharmaceutically acceptable salt thereof, wherein: L19 and A are each independently CH or N; 2026223382   31 Aug 2026 Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, ”C(=O)N(Ri3)(Ri4), --- (CHi)qC( O)X(Ri3)(Ru). CF3, OCF'3, or S(O) R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cj-6 alkyl, C1-6 alkoxy, or ~-N(Ri3)(R]4); R2 is hydrogen, halo, Ci-6 alkoxy, or Cj-6 alkyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, Cue alkyl, Ct-6 alkoxy, CF3, -OCF3, or -S(=0)2R2o; R39 is hydrogen, C1-6 alkyl, or C1-6 alkoxy; R44 and R45 are each independently hydrogen, C1-6 alkyl, Cj-6 alkoxy, cycloalkyl, hydroxyalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, -S(=O)2R20, -C(=O)R, or -N(R13R14); and R13 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -NfRisRie), or -S(=0)2R2o; and Ris and Rie are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino.

[00319] In certain aspects of Structure (VUI), Ri is hydrogen, cyano, C1-6 alkyl, C1-6 alkoxy, or -C(=O)NN(R13)(R14).

[00320] In certain aspects of Structure (VIII), Ri is cyano.

[00321] In certain aspects of Structure (VUI), R2 is hydrogen or halo.

[00322] In certain aspects of Structure (VIII), R2 is hydrogen.

[00323] In certain aspects of Structure (VUI), R3 is hydrogen.

[00324] In certain aspects of Structure (VUI). R21 and R22 are each independently hydrogen or Ci-6 alkyl.

[00325] In certain aspects of Structure (VIII), R21 and R22 are each independently C1-6 alkyl.

[00326] In certain aspects of Structure (VIII), R39 is hy drogen.

[00327] In certain aspects of Structure (VIII), L19 is N.

[00328] In certain aspects of Structure (VIII), A is N.

[00329] In certain aspects of Structure (VIII), A is CH.

[00330] In certain aspects, the compounds of Structure (VIII) have the following Structure (Vin-D): 2026223382   31 Aug 2026 (VIII-D) or a pharmaceutically acceptable salt thereof. 1003311 In various aspects, compounds of formula IX are provided: (IX) or a pharmaceutically acceptable salt thereof, wherein: R1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-fCs-Cs cycloalkyl) or -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each Rz is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH -(C1-C4 alkyl)t-Ot-(C3-C5 cycloalkyl), or -(C1-C4 alkyl).-O-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; 2026223382   31 Aug 2026 the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L! is CR23 or N; L2 is CH or N; at least one of L1 or L2 is N; and R23 is H or C1-C4 straight or branched alkyl.

[00332] In some aspects of Structure (IX), R24 is Cu-Cr straight or branched alkyl, -(C1-C4 alkyl)t-O-(Ct-C4 straight or branched alkyl) wherein t is 0 or 1.

[00333] In some aspects of Structure (IX), R21 is halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom, -S(O)u-(Cj-C4 straight or branched alkyl) wherein u is 0 or 2, or -S(O)u-( C3-C5 cycloalkyl) wherein u is 0 or 2;

[00334] In some aspects of Structure (IX), R3 is H or halogen.

[00335] In some aspects of Structure (IX), R1 is halogen, -CN or C1-C2 haloalkyl.

[00336] In some aspects of Structure (IX), both L1 and L2 are N.

[00337] In some aspects of Structure (IX), R21 is C1-C2 alkyl or C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[00338] In some aspects of Structure (IX), R21 is C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[00339] In some aspects of Structure (IX), R24 is -(C1-C2 alkyl)t-O-(Ci-C2 alkyl) wherein t is 0 or 1.

[00340] In some aspects of Structure (IX), R21 is C3-C5 cycloalkyl, R22 is C1-C2 alkyl and R24 is C1-C2 alkyl.

[00341] In some aspects of Structure (IX), R21 is cyclobutyl, R22 is C1-C2 alkyl and R2" is C1-C2 alkyl.

[00342] In some aspects of Structure (IX), R2! is cyclobutyl.

[00343] In some aspects of Structure (IX), R3 is H or F.

[00344] In some aspects of Structure (IX), R! is -CN.

[00345] In some aspects of Structure (IX), R1 is ~CF3.

[00346] In some aspects of Structure (IX), R22 is H, methyl or ethyl.

[00347] In some aspects of Structure (IX), R22 is H.

[00348] In some aspects of Structure (IX), R22 is methyl. 2026223382   31 Aug 2026

[00349] In some aspects of Structure (IX), R3 is -CN, each R2 is hydrogen, R3 is H or F, R21 is C3-C4 cycloalkyl, R" is methyl, L1 and L2 are N, and R24 is methyl, ethyl, hydroxymethyl, methoxymethyl, 2-methoxy ethyl.

[00350] In some aspects of Structure (LX), R1 is -CN, each R2 is H, R' is H or F, R2! is C3-C4 cycloalkyl, R22 is methyl, L1 and L2 are N, and R24 is methoxy or ethoxy.

[00351] In some aspects of Structure (IX), R1 is -CN, each R2 is H, RJ is H or F, R2! is C3-C4 cycloalkyl, R22 is methyl, L! is CH, L2 is N, and R24 is methyl, ethyl, hydroxymethyl, methoxymethyl, or 2-methoxyethyl.

[00352] In some aspects of Structure (IX), R1 is -CN, each R2 is H, R3 is H or F, R21 is C3-C4 cycloalkyl, R22 is methyl, L1 is N, L2 is CH, and R24 is methyl, ethyl, hydroxymethyl, methoxymethyl, or 2-methoxyethyl.

[00353] In some aspects of Structure (IX), compounds have a structure selected from the group consisting of:

[00354] In various aspects, compounds of Structure (X) are provided: or a pharmaceutically acceptable salt thereof, wherein: 2026223382   31 Aug 2026 R'1 is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(Cs-C5 cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH or halogen; L3 is C(R60)2, 0 or NR50; each R60 is independently H, -OH, -CN, -Ot-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl), or -C(O)-N(R60{)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; each R50 is independently H, -C(O)-Ot-(Ci-C4 straight or branched alkyl), -C(O)-Ot-(C3-Cs cyclic alkyl), -C3-C5 cyclic alkyl optionally containing an oxygen or nitrogen heteroatom, -C(O)-N(R501)2, C1-C4 straight or branched alkyl wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R2! is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom R22 is H, halogen, C1-C2 alkyl; each Rzo is independently -OH, -CN, halogen, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-Ot-(C3-Cs cycloalkyl), -(C1-C4 alkyl)t-O-(Ci-C4 straight or branched alkyl), -C(0)-0r(Ci-C4 alkyl), or -C(O)-N(R501)2 wherein: t is 0 or 1, and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, I or 2; each R601 and R501 is independently H or C1-C4 straight or branched alkyl; and wherein two of R26, R60, R3°, R501 and R601 optionally join to form a ring wherein the two of R26, R60, R50, R50! and R601 may be two R26, two R60, two R50, two R501 or two R60i. 2026223382   31 Aug 2026

[00355] In some aspects of Structure (X), R21 is halogen, C1-C4 straight or branched alkyl or C3-C5 cycloalkyl. 100356]       In some aspects of Structure (X), R is H or halogen.

[00357] In some aspects of Structure (X), R1 is -CN or C1-C2 haloalkyl.

[00358] In some aspects of Structure (X), R3 is H or F.

[00359] In some aspects of Structure (X), R1 is -CN.

[00360] In some aspects of Structure (X), R1 is-CF3.

[00361] In some aspects of Structure (X), n is 1.

[00362] In some aspects of Structure (X), n is 2.

[00363] In some aspects of Structure (X), m is 1

[00364] In some aspects of Structure (X), m is 2.

[00365] In some aspects of Structure (X), R21 is C1-C2 alkyl or C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[00366] In some aspects of Structure (X), R21 is C3-C5 cycloalkyl and R22 is C1-C2 alkyl.

[00367] In some aspects of Structure (X), n is 2, m is 1, L3 is -N-C(O)-O-(Ci-C2 alkyl).

[00368] In some aspects of Structure (X), L3 is NR50; R50 is C1-C2 alkyl; R21 is cyclobutyl; R22 is H or methyl; R3 is H; R1 is -CN; m is 2 and n is 1 or 2.

[00369] In some aspects of Structure (X), n is 2, m is 1, LJ is O and s is 0.

[00370] In some aspects of Structure (X), Rzz is H, methyl or ethyl.

[00371] In some aspects of Structure (X), R22 is methyl.

[00372] In some aspects of Structure (X), R22 is H.

[00373] In some aspects of Structure (X), R1 is -CN, each R2 is H, R' is H or F, R21 is C3-C4 cycloalkyl, R22 is methyl, n is 2 and L3 is NR50 where R50 is methyl or ethyl.

[00374] In some aspects of Structure (X), R1 is -CN, each R2 is H, R3 is H or F, R21 is C3-C4 cycloalkyl, R22 is methyl, n is 2 and L3 is O.

[00375] In some aspects of Structure (X), the compound has a structure selected from the group consisting of: 2026223382   31 Aug 2026 N

[00376] In various aspects, compounds of Structure (XI) are provided: O O or a pharmaceutically acceptable salt thereof, wherein: R! is H, -GN, halogen, C1-C4 straight or branched alkyl, -O-(Cs-C5 cycloalkyl), -O-(Cj-C4 straight or branched alkyl) wherein: the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently H, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R2’1 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R22 is H, halogen, C1-C2 alkyl; and R33’1 is C1-C2 alkyl or C2-O-(Ci or C2 alkyl).

[00377] In some aspects of Structure (XI), R3 is H or halogen.

[00378] In some aspects of Structure (XI), R1 is halogen, -CN or C1-C2 haloalkyl.

[00379] In some aspects of Structure (XI), R21 is C3-C4 cycloalkyl and R22 is C1-C2 alkyl.

[00380] In some aspects of Structure (XI), Rzl is cyclobutyl and R22 is C1-C2 alkyl.

[00381] In some aspects of Structure (XI), R21 is cyclobutyl.

[00382] In some aspects of Structure (XI), R3 is H or F. 2026223382   31 Aug 2026

[00383] In some aspects of Structure (XI), R! is -CN.

[00384] In some aspects of Structure (XI), R1 is -CF3. 100385]       In some aspects of Structure (XI), Rzz is H, methyl or ethyl.

[00386] In some aspects of Structure (XI), R22 is H.

[00387] In some aspects of Structure (XI), Rzz is methyl.

[00388] In some aspects of Structure (XI), R1 is -CN, each R2 is H, RJ is H or F, R2! is cyclobutyl, R22 is methyl and R,5f is methyl or ethyl.

[00389] In some aspects of Structure (XI), the compound has a structure selected from the group consisting of:

[00390] In certain aspects, the present disclosure provides compounds having any one of the structures found in Table 1. According to the present disclosure, the compounds of Table 1 are inhibitors of fatty acid synthase. Synthesis of Compounds

[00391] Also described herein are methods of synthesizing the compounds of the present disclosure. Compounds of the present disclosure can be synthesized as indicated in SYNTHETIC SCHEMES 1-13 below. 2026223382   31 Aug 2026 Scheme 1 wherein: R" is hydrogen or alkyl; Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ct-6 alkoxy, -C(=O)N(Rb)(R14), -(CH2)qC(=O)N(Ri3)(Ri4), CF3, -OCF3, or S( ¢)) K -< q is 0, 1, 2, 3, or 4; Ro is hydrogen or Cj-6 alkyl, Ci-s alkoxy, or -N(Rh)(R14); R2 is hydrogen, halo, Ci-6 alkoxy, or Cj-6 alkyl; R is hydrogen, hydroxyl, halo, C1-6 alkyl, or Ci-s alkoxy; Ri and R22 are each independently hydrogen, halo, cyano, Cne alkyl, C1-6 alkoxy, CF3, -OCF3, or S( ObRso R13 and Ri4 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R15R16), or -S(=0)2R2o; 2026223382   31 Aug 2026 Ris and Ri6 are each independently hydrogen, Ci-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; and R17 is hydrogen or alkyl. Scheme 2 R23 and / or R23 wherein: Ri is hydrogen, cyano, halo, Ci-s alkyl, C1-6 alkoxy, -C(=O)N(Ri3)(Ri4), -(CH '.kCC 0}X(Rh)(Ru).. CF3, -OCF3, or-S(=0)2R2o; q is 0, 1, 2, 3, or 4; R20 is hydrogen or C1-6 alkyl, C1-6 alkoxy, or --N(R13)(R14), R2 is hydrogen, halo, C1-6 alkoxy, or C1-6 alkyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; 2026223382   31 Aug 2026 R21 and R22 are each independently hydrogen, halo, cyano, Ci-6 alkyl, Ci-6 alkoxy, CF3, -OCF3, or S( O VR 'w: R13 and R14 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, ~N(Rt5Ri6), or -S(=0)2R2o; Ris and Ri6 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; R23 is hydrogen, -N(Rb)(Rj4), Ci-e alkyl, C1-6 alkoxy, is absent if Li is N, or R23 and R24 taken together with the atoms to which they are attached join together to form a heterocyclyl, heteroaryl, or cycloalkyl; and R24 is hydrogen, -N(R13)(Rm), C1-6 alkyl, Ci-6 alkoxy, -(Ci-6 alkoxy)(heterocyclyl), heterocyclyl, or R23 and R24 taken together with the atoms to which they are attached join together to form a heterocyclyl, heteroaryl, or cycloalkyl. Scheme 3 wherein: LG is a leaving group; Nu is a nucleophile; L2,1-3, L4, and L4’ are each independently CH or N; 2026223382   31 Aug 2026 Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, ”C(=O)N(Ri3)(Ri4), --- (CHi)qC( O)X(Ri3)(Ru). CF3, OCF'3, or S(O) R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cj-6 alkyl, Cj-6 alkoxy, or ~-N(Ri3)(R]4); R2 is hydrogen, halo, Ci-6 alkoxy, or Cj-6 alkyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Ct-6 alkoxy, CF3, -OCF3, or -S(=0)2R2o; R13 and Ru are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(Rt5Ri6), or -S(=0)2R2o; Ris and R16 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; and R17 is hydrogen or alkyl. Scheme 4 9 edci 0 R24 OH H2NNH2 R24^NHNH2 2026223382   31 Aug 2026 Ri is hydrogen, cyano, halo, Ci-6 alkyl, Ci-6 alkoxy, ”C(=O)N(Ri3)(Ri4), (O HqC( OlX'iRi -•)(Ru). CFh, --OCF3, or S( 0) R20; q is 0, 1, 2, 3, or 4; R20 is hydrogen or Cj-6 alkyl, Cj-6 alkoxy, or -N(R13)(R]4); R2 is hydrogen, halo, Ci-6 alkoxy, or Cj-6 alkyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; R21 and R22 are each independently hydrogen, halo, cyano, C1-6 alkyl, Ct-6 alkoxy, CF3, -OCF3, or -S(=0)2R2o; R13 and Ru are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(Ri5Ri6), or -S(=0)2R2o; Ris and R16 are each independently hydrogen, C1-6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; R17 is hydrogen or alkyl; and R24 is hydrogen, -N(R13)(R14), C1-6 alkyl, C1-6 alkoxy, -(C1-6 alkoxy)(heterocyclyl), or heterocyclyl. 2026223382   31 Aug 2026 Scheme 5 wherein: Ri is hydrogen, cyano, halo, Ci-s alkyl, Ci-6 alkoxy, -C(=O)N(R13)(R14), 4CH2)qC(=O)N(Ri3)(Ri4), CF3, “OCF3, or-S(=0)2R2o; 2026223382   31 Aug 2026 q is 0, 1, 2, 3, or 4; Rao is hydrogen or Ci-6 alkyl, Ci-6 alkoxy, or -N(Ri3)(Ri4); R2 is hydrogen, halo, C1-6 alkoxy, or C1-6 alkyl; R3 is hydrogen, hydroxyl, halo, C1-6 alkyl, or C1-6 alkoxy; Rai and R22 are each independently hydrogen, halo, cyano, Cue alkyl, Ct-6 alkoxy, CF3, -OCF3, or -S(=0)2Rao; R13 and Ru are each independently hydrogen, Cue alkyl, cycloalkyl, aryL heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(Rt5Ri6), or -S(=0)2Rao; Ris and Ri6 are each independently hydrogen, Cue alkyl, cycloalkyl, aryL heterocyclyl, heteroaryl, hydroxyalkyl, or alkylamino; R17 is hydrogen or alkyl; R24 is hydrogen, -N(R13)(R14), C1-6 alkyl, C1-6 alkoxy, -(C1-6 alkoxy)(heterocyclyl), or heterocyclyl; R29 is hydrogen, C1-6 alkyl, C1-6 alkoxy, hydroxyalkyl, heteroaryl, heterocyclyl, -N(Ri5Ri6), “C(=O)R46, or -R48C(=O)R47; R34 is hydrogen, C1-6 alkyl, C1-6 alkoxy, cycloalkyl, hydroxyl, hydroxyalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, CF3, -OCF3, -S(=O)2R20, or -N(RisR16); and m 0, 1, or 2.

[00392] Schemes 6-13 provides a synthesis for exemplary compounds of formula IX wherein: R! is H, -CN, halogen, C1-C4 straight or branched alkyl, -O-(C3-Cs cycloalkyl), -O-(Ci-C4 straight or branched alkyl) wherein: C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; and when R1 is not H, -CN or halogen, it is optionally substituted with one or more halogens; each R2 is independently hydrogen, halogen or C1-C4 straight or branched alkyl; R3 is H, -OH, or halogen; R21 is H, halogen, C1-C4 straight or branched alkyl, C3-C5 cycloalkyl wherein the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R22 is H, halogen, or C1-C2 alkyl; R23 is H or C1-C4 straight or branched alkyl; and 2026223382   31 Aug 2026 R24 is H, C1-C4 straight or branched alkyl, -(C1-C4 alkyl)t-OH, -(C1-C4 alkyl).-Ot-(C3-C5 cycloalkyl), or -(Ci-O alkyl)rO-(Ci-C4 straight or branched alkyl) wherein: t is 0 or 1; and the C3-C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom. Scheme 6 0 2026223382   31 Aug 2026 Scheme 7 '' 'OH N«:Q«, I* KjSO^           OH xo" ' o' ' w ' K>'    : '              ACOH Rf’ -S- H, O O                         O O -x X .,            ..,                                              A .., ii                                      H O J. ,1J >3,, R.....J J T OR, -■ Rs 'O 'V ' MeC<H R?s' Rs '■' ^ NaHCOs ' / "'Ri                              ''y^Rs R,                                  A N ' N O KOH Rs'"\ A .-, :i MeOHw H h ;i 1.¾ SKSH R. Scheme 8 ESC!. HOBS. DtPSA. DMF {•:                                                         J                                                                .                           p\c -0--^--¾. NIS'H^ VY\^' zmCNfe.m^sJ, 'o' Y'Y' rwho* ,, -Ax,A„......................*" ,, >L,yA., ..........................”                MsOH * 248 Scheme 10 249 Scheme 11 2026223382   31 Aug 2026 Scheme 12 Ar-M .......OH ------ £5Ci. HO», DfPEA, DMF Sult: Shen :...... Q~8f Pc. ;?XCNh : '■ U. QO ECCL CT. IWEA. OMF R>< k A. ,.<x    1}¾ PyrtSne            < ■             w XN 2026223382   31 Aug 2026 Scheme 13

[00393] Additional methods for producing particular compounds according to the present disclosure are provided in the EXAMPLES. One skilled in the art will recognize that other compounds of structures can be made by modifications to the specifically disclosed schemes employing methods known to those of skill in the art. Additional examples can be found in Table 1.

[00394] Many such techniques are well known in the art. However, many of the known techniques are elaborated in Compendium of Organic Synthetic Methods (Vol. 1, 1971; Vol. 2, 1974; Vol. 3, 1977; Vol. 4, 1980; Vol. 5, 1984; and Vol. 6 as well as March in Advanced Organic Chemistry (1985); Comprehensive Organic Synthesis. Selectivity, Strategy & Efficiency in Modern Organic Chemistry. In 9 Volumes (1993); Advanced Organic Chemistry Part B: Reactions and Synthesis, Second Edition (1983); Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, Second Edition (1977); Protecting Groups in Organic Synthesis, Second Edition; and Comprehensive Organic Transformations (1999). Viral Infection Pathways

[00395] The host cell targets inhibited by the present compounds and methods play a role in the viral replication and / or infection pathways. Targeting of such host cell targets modulates the replication and / or infection pathways of the viruses. In preferred aspects the identified host cell targets are directly or indirectly modulated using the compositions of the present disclosure. The 2026223382   31 Aug 2026 modulation of such host cell targets can also be performed by targeting entities in the upstream or downstream signaling pathways of the host cell targets.

[00396] According to the present disclosure, viral infection can be treated by targeting the fatty acid synthesis pathway, and in particular fatty acid synthase. HRV is representative of viruses that can be treated according to the present disclosure. Like other viruses, the replication of HRV involves six phases; transmission, entry, replication, biosynthesis, assembly, and exit. Entry occurs by endocytosis, replication and vRNP assembly takes place in the nucleus, and the virus buds from the plasma membrane. In the infected patient, the virus targets airway epithelial cells. The present compounds and methods target and modulate at least one host cell targets involved in such pathways.

[00397] For some viruses a great deal of progress has been made in the elucidation of the steps involved during infection of host cells. For example, experiments initiated in the early 1980s showed that influenza virus follows a stepwise, endocytic entry program with elements shared with other viruses such as alpha-and rhabdoviruses (Marsh and Helenius 1989; Whittaker 2006). The steps include: 1) Initial attachment to sialic acid containing glycoconjugates receptors on the cell surface; 2) signaling induced by the virus particle; 3) endocytosis by clathrin-dependent and clathrin-independent cellular mechanism; 4) acid-induced, hemaglutinin (HA)-mediated penetration from late endosomes; 5) acid-activated, M2 and matrix protein (Ml) dependent uncoating of the capsid; and, 6) intra-cytosolic transport and nuclear import of vRNPs. These steps depend on assistance from the host cell in the form of sorting receptors, vesicle formation machinery, kinase-mediated regulation, organelle acidification, and, most likely, activities of the cytoskeleton.

[00398] Influenza attachment to the cells surface occurs via binding of the HAI subunit to cell surface glycoproteins and glycolipids that carry oligosaccharide moieties with terminal sialic acid residues (Skehel and Wiley 2000). The linkage by which the sialic acid is connected to the next saccharide contributes to species specificity. Avian strains including H5N1 prefer an a-(2,3)-link and human strains a-(2,6)-link (Matrosovich 2006). In epithelial cells, binding occurs preferentially to microvilli on the apical surface, and endocytosis occurs at base of these extensions (Matlin 1982). Whether receptor binding induces signals tha...

Claims

1. A method of treating acne, wherein the method comprises administering to a patient in need thereof a fatty acid synthase inhibitor of Formula:, or a pharmaceutically acceptable salt thereof, wherein moieties depicted in the Formula which exist in multiple tautomeric forms include all such forms.

2. Use of a fatty acid synthase inhibitor for the manufacture of a medicament for the treatment of acne in a subject in need thereof, wherein the fatty acid inhibitor is of Formula:, or is a pharmaceutically acceptale salt thereof, wherein moieties depicted in the Formula which exist in multiple tautomeric forms include all such forms.

Images